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Historical Perspective
The nurse of the Mediterranean
Saviour Pisani
During the First World War Malta did not take an active part 
in the fighting.  Britain was joined in an ‘entente’ a friendship 
agreement with France since 1904 and later with Russia in 
1907.  On the other hand Germany was allied to the Austrian-
Hungerian Empire, hence when the Great War started in July 
1914 there were France, Britain and Russia on one side and 
Germany and Austria-Hungary on the other.  The British fleet 
“ruled the waves”, hence with France and Britain as allies, to 
be joined later by Italy, the Mediterranean was more or less an 
allied lake, with Malta in the centre.
During the nineteenth century the Ottoman Empire was 
falling apart, and one of the big problems that faced the foreign 
office of Britain in the nineteenth century was the Ottoman 
Empire known as the sick man of Europe.    Russia was looking 
at it from the part of the chief inhibitor of its demise, while 
Britain was taking the role of a doctor.  Russia is a vast country, 
stretching from the Baltic to the Pacific and from the Arctic to the 
Black Sea.  Its biggest problem was that it could not use its ports 
throughout the whole year.  Its arctic port, the Archangel, was 
blocked by ice; its Baltic ports had a similar problem in winter. 
Furthermore the Baltic Sea was dominated by the German navy 
in XXXII.  The latter was secondary to that of Britain. Russia’s 
far eastern ports – Vladivostostock – was also frozen and far too 
distant.  The Black Sea ports were closed by the Ottoman Empire 
during hostilities.  The Russian ships had to pass through the 
Dardanelles to reach the Mediterranean and if the Dardanelles 
were under a hostile power no merchant ship could pass – i.e. 
the Russian navy was bottled up in the Black Sea.
The British were always suspicious of the Russian intentions 
towards the Ottoman Empire, and the Crimean War of 1854 
was fought by Britain, France and the Ottoman Empire against 
Russia to destroy its main base of Sevastapol and its fleet.  By 
the treaty of San Stefano and the convention of Berlin blocked by 
Bismarck, the small Balkan states of Bulgaria, Serbia, Rumania 
and Montenegro appeared and these showed that they were very 
jealous of their independence and were far more efficient than 
the decadent Ottoman Empire to thwart Russian ambitions 
to enter the Mediterranean Sea. Still the Balkans was not so 
stable and in 1911-1912 the Balkan Wars erupted.  In 1914 
after the Archduke Ferdinand was assassinated in Sarajevo, 
Austria-Hungary declared war on Serbia and the First World 
War started.  The Ottoman Empire had a friendly relationship 
with Germany, its military was trained by Prussian officers and 
when the battle cruisers – Goeben and Breslan – were caught in 
the Mediterranean in July 1914 and sailed on to Constantinople 
where they were given as a present to the Sultan, the Ottoman 
Empire found itself on the German side together, incidentally 
with Bulgaria which felt short-changed by Serbia.
The First World War started in high spirits by both sides. 
However, it soon degenerated in trench warfare.  The British 
old professional army, known as the old contemptible was soon 
decimated and new regiments came from Britain and its empire 
to replace the heavy losses.  The French also lost many soldiers 
when they moved on Alsace and Lorraine, lost in 1870.  The 
Russians lost thousands and thousands of soldiers in the battle 
of Tannenberg.  Their equipment was found most wanting and 
it was clear to all military chiefs that Russia could not sustain 
a war of attrition.  The soldiers went into battle without rifles, 
they had to pick rifles from dead or wounded colleagues as they 
advanced along the front.  The Russian army needed munitions, 
heavy guns, transport, rifles and all that a modern war entails. 
The French knew that if the Russian front were to collapse – as 
it did later in the war, the full fury of the German army would be 
let loose on them.  The only way available to supply them was by 
sea.  The Baltic Sea was dominated by the German fleet, while 
the Archangel was hardly practical.  Hence Winston Churchill, 
who was lord of the Admirality at that time, thought of supplying 
the Russian army from its Black Sea ports.  To do this he had 
to open the Dardanelles to allied shipping, which really meant 
he had to knock the Ottoman empire out of the war.  This he 
deemed a not so difficult task - after all the Ottoman Empire 
had been falling apart for more than a century, and it was kept 
in one piece thanks to the efforts of the British Government, the 
Saviour Pisani
Department of Anaesthesia, Mater Dei Hospital
Keywords
nurse, Mediterranean, first world war, Rupert Brooke
Malta Medical Journal    Volume 22   Issue 03   2010 1
MMJMalta Medical Journal
Volume 22 • Issue 03 • 2010
www.mmj-web.orgUniversity of Malta
Medical School
As combination therapy with other widely prescribed agents
Adding JANUVIA™ delivers substantial 
glucose reductions for a broad range of 
patients with type 2 diabetes
In clinical studies,2
•  Substantial HbA1c reductions through a  
physiologic mechanism of action
•  Generally weight-neutral therapy with  
a low risk of hypoglycemia
•  Generally well-tolerated therapy
•  Always once-daily dosing
Once-daily
(sitagliptin/metformin, MSD)
JANUVIA™ (sitagliptin) and  JANUMET™ (sitagliptin/metformin) are trademarks of Merck & Co., Inc., Whitehouse 
Station, NJ, USA.
Copyright © 2008 Merck & Co., Inc.  All rights reserved. 10–09 JAN-2008-W-1272306-J
19-Jan-2010 JMT-2009-GULF(CYPRUS-MALTA)-1704-J
For patients not controlled on metformin
JANUMET™ provides powerful 
HbA1c reductions to help more patients 
with type 2 diabetes get to goal
In clinical studies,
•  Powerful HbA1c reductions to help more 
patients get to goal (HbA1c goal <7%)2
•  Weight loss and less hypoglycemia (with 
sitagliptin 100 mg + metformin) vs a 
sulfonylurea + metformin3
•  Comprehensive mechanism that targets  
3 key defects of type 2 diabetes2
Before  prescribing, please consult the full Prescribing Information.
JANUVIA can be used as an adjunct to diet and exercise 
in combination with metformin, glitazone, sulfonyurea, or 
sulfonylurea + metformin when the current regimen does not 
provide adequate glycemic control. 
JANUVIA is contraindicated in patients who are hypersensitive to any 
components of this product.
When JANUVIA is used in combination with sulfonylurea, a lower 
dose of the sulfonylurea may be considered to reduce the risk of 
hypoglycemia. 
Clinical study experience with JANUVIA in patients with moderate 
or severe renal insufficiency is limited. Therefore, use of JANUVIA is 
not recommended in this patient population. 
Before prescribing, please consult the enclosed full Prescribing Information.
JANUMET is contraindicated in patients with: hypersensitivity to the active substances or to 
any of the excipients; diabetic ketoacidosis, diabetic pre-coma; moderate and severe renal 
impairment (creatinine clearance < 60 ml/min); acute conditions with the potential to alter renal 
function such as: dehydration, severe infection, shock, intravascular administration of iodinated 
contrast agents; acute or chronic disease which may cause tissue hypoxia such as: cardiac or 
respiratory failure, recent myocardial infarction, shock; hepatic impairment; acute alcohol 
intoxication, alcoholism; lactation. 
For patients with type 2 diabetes mellitus: JANUMET is indicated as an adjunct to diet 
and exercise to improve glycemic control in patients inadequately controlled on their 
maximal tolerated dose of metformin alone or those already being treated with the 
combination of sitagliptin and metformin. JANUMET is also indicated in combination 
with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and 
exercise in patients inadequately controlled on their maximal tolerated dose of 
metformin and a sulphonylurea. 
When JANUMET is used in combination with a sulfonylurea, a lower dose of 
the sulfonylurea may be considered to reduce the risk of hypoglycemia.
References: 1. IMS Health, NPA Plus™, October 2006 – 3 October 2008. 2. 
Data on file, MSD Cyprus and Malta. 3. Nauck MA, Meininger G, Sheng 
D, et al; for Sitagliptin Study Group 024. Efficacy and safety of the 
dipeptidyl peptidase-4 inhibitor, sitagliptin, compared to the 
sulfonylurea, glipizide, in patients with type 2 diabetes 
inadequately controlled on metformin alone: a 
randomized, double-blind, non-inferiority trial. 
Diabetes Obes Metab. 2007;9:194–205. 
Malta Medical Journal    Volume 22   Issue 03   2010 3
Malta Medical Journal
Volume 22 • Issue 03 • 2010
University of Malta Medical School
Mater Dei Hospital, Msida, Malta
Email: mmj-editor@um.edu.mt
www.mmj-web.org
Editorial Board
Chairman
Joseph M. Cacciottolo MD, DSc
Editor
Josanne Vassallo MD, PhD
Members
Jürgen Abela MRCGP, FRCGP
Simon P. Attard Montalto MD, FRCPCH
Neville Calleja MD, MSc
Simon Camilleri MSc, MOrthRCS
Anthony G. Fenech BPharm(Hons), PhD
David Pace MD, MRCPCH
Charles Savona-Ventura MD, DScMed
Stephen C Sciberras MRCP, DESA
Malta Medical Journal
ISSN 1813-3339
© MMJ 2010
All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval 
system, or transmitted in any form or by other means, electronic, mechanical, 
photocopying, recording or otherwise without prior permission, in writing, 
of the MMJ Editorial Board.
All articles published in the Malta Medical Journal, including editorials, represent the 
opinion of the authors and do not reflect the official policy of the University of Malta or the 
institution with which the author is affiliated, unless this is clearly specified. The appearance 
of advertising in the Journal is not a guarantee or endorsement of the product or the claims 
for the product by the manufacturer. The Editorial Board disclaims any responsibility or 
liability for non-compliance of advertising artwork to Regulatory Units.
Published by: Faculty of Medicine and Surgery, University of Malta
Design and production: www.outlook.coop
MMJ
Volume 22 • Issue 03 • 2010
Malta Medical Journal
Mark Muscat
Tuscany
acrylics on canvas, 23.5 x 18.0cm, July 2010
Dr Mark Muscat currently works as EUVAC.NET scientific 
co-ordinator at the Statens Serum Institut, Department of 
Epidemiology in Copenhagen, Denmark.
For instructions to authors, refer to website at
www.mmj-web.org/instruct.pdf
 5 Publish or perish?
  Editorial
 6 Pharmacotherapeutic aspects 
  of dementia care in Malta
  Charles Scerri, Stephen Abela, Anthea Innes
 14 Pulmonary rehabilitation: 
  insight into current trends 
  Anabel Sciriha, Stephen Montefort
 18 Management of inflammatory dentigerous  
cysts in children: report of two cases
  Erica Scerri, Alexander Azzopardi
 21 A rare cause of hypoglycaemia
  Robert Sciberras
 24 Implementation of a graft surveillance 
programme for infrainuginal vascular  
bypass surgery
  Noel Cassar, Branko Dunjic, Kevin Cassar
 27 The nurse of the Mediterranean
  Saviour Pisani
 31 Professional medical journal publications  
in Malta
  Charles Savona Ventura
A
C
L 
A
d 
12
/1
0 
M
T
Malta Medical Journal    Volume 22   Issue 03   2010 5
Editorial
Publish or perish?
This issue of the Malta Medical Journal contains a historical 
perspective on medical publications in Malta over the years 
and it is a tribute to the medical community that over the last 
one hundred and seventy years, dedicated members of that 
profession have  published articles of relevance to the practice of 
medicine in the Maltese Islands. The aim has been to highlight 
problems particular to the epidemiology, pathophysiology and 
management of disease endemic in Malta.
In a country with a population of just over 400,000, the 
survival of such publications has depended on a number of 
different factors – infrastructural, financial, and by the very 
nature of their content, relatively limited circulation with the 
resultant implications for indexing and the acquisition of an 
impact factor.  Ultimately until recently the limited resources 
available to local researchers wishing to address specific 
hypotheses with the aim of improving patient centred medical 
care also impacted on the volume of scientific activity going 
on. 
In this issue, there are articles related to chronic non 
communicable disease which are having a significant impact 
on patient morbidity and mortality and the healthcare budget 
namely chronic respiratory problems and dementia. The 
provision of cost effective healthcare with rehabilitation and 
devolvement of patient care to the community represent major 
public health challenges at present and the identification of 
lacunae in service provision is the initial step in the development 
of national health strategies in chronic non-communicable 
diseases such as these two. The implementation of such 
strategies mandates the use of auditing and of analysis re local 
concordance with international established standards of health 
care. Genetic, cultural and health service structures differ 
in individual countries and in specific regions in individual 
countries. Hence the need to ensure that proposed measures 
and treatments are appropriate to the specific population in 
this case the Maltese population. 
Subsequent to the establishment of postgraduate training 
programs, young trainees are now keen to research and publish 
and the Faculty of Medicine now has seen a significant increase 
in the number of students undertaking Masters and Doctoral 
studies. It is now possible to apply for research funds  and a 
number of courses are available that focus on grantsmanship, 
research, statistics and scientific writing. The Malta Medical 
Journal which is published online and also in hard copy, 
provides such young researchers with a forum to publish their 
observations, under the supervision and with the help of their 
more senior colleagues.
This increase in research activity and publication will 
hopefully continue to increase over the coming years reflecting 
the local medical community’s  healthy constructive critical 
attitude to work published in the international medical 
community and its relevance to the practice of medicine in 
Malta.
Josanne Vassallo
Editor
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Review Article
Pharmacotherapeutic aspects 
of dementia care in Malta
Abstract
Dementia is the most common neurodegenerative disorder 
of old age affecting one percent of the local general population. 
It is a major predictor of morbidity and mortality in the elderly, 
adding a significant burden on health and social care systems 
across Europe. The financial impact of caring for individuals 
with dementia is considerable and progressive loss of cognitive 
function does not only pose challenges to the patients but 
also adds significant strain on the well-being of caregivers 
and family members. Although no cure is available, disease 
progression can be delayed by early intervention and by the 
use of pharmacotherapeutic agents that interfere with central 
neurotransmitter systems involved in cognitive processes. 
This review presents current trends in pharmacotherapeutic 
intervention in dementia care together with caregiver 
perceptions on treatment expectations in Malta.   
Charles Scerri, Stephen Abela, Anthea Innes
Introduction
Dementia is a complex clinical syndrome associated with 
behavioural, cognitive and personality changes. It usually 
presents itself as impairment in memory, abstract thinking, 
impaired judgment and other disturbances that are of such 
severity that they interfere with work and social activities.1 
Several diseases are known to cause dementia. Alzheimer’s 
disease (AD) accounts for 50-70% of cases followed by Vascular 
dementia, Lewy Body Disease, fronto-temporal dementia and 
dementia secondary to disease.2 According to an estimate from 
World Health Organization (WHO), dementia is responsible for 
more years lived with disability in people older than 60 years 
(11.2%) than stroke (9.5%), cardiovascular disease (5%) or all 
forms of cancer (2.4%).3 Currently, there are more than 7.3 
million people with dementia in Europe, a figure that is expected 
to double by the next 30 years.4 This will result in a growing 
burden on health care resources and family members who, in 
the majority of cases, provide informal care at home. A recent 
study estimated that approximately one percent of the general 
population in Malta has dementia, a figure that is expected to 
increase significantly by the year 2050 (Table 1).5
Over the last two decades, a number of therapeutic strategies 
have been developed for the symptomatic management of 
the most common forms of dementia, particularly AD. The 
latter is characterised by the presence of amyloid plaques and 
neurofibrillary tangles coupled with significant degeneration of the 
central cholinergic system resulting in cognitive decline.6 Indeed, 
the first pharmacological agents to be approved for symptomatic 
treatment of AD were the acetylcholinesterase inhibitors which 
mainly block the enzyme acetylcholinesterase thus increasing 
the concentrations of the neurotransmitter acetylcholine in the 
synaptic area (Table 3). Studies showed that the use of these drugs 
(namely donepezil, galantamine and rivastigmine) significantly 
improved cognition and activities of daily living.7 Another drug 
that is also available in the therapeutic management of AD is 
the glutamatergic-system modifier memantine which partially 
blocks glutamate-induced overstimulation of the N-methyl-
D-aspartate (NMDA) receptor thus reducing calcium-induced 
cytotoxicity (Table 3). In randomised clinical trials, this drug 
demonstrated the ability to delay cognitive and functional decline 
without any significant incidence of side effects.8,9 According to the 
latest guidelines issued by the UK National Institute for Clinical 
Excellence (NICE), acetylcholinesterase inhibitors should be 
recommended for use in moderate AD whereas memantine should 
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Table 1: Current and projected number of total dementia cases in the Maltese islands (adapted from Abela et al).5
Year 30-59 60-64 65-69 70-74 75+ Total cases % of total 
population
2010 203 293 316 629 2947 4388 1.12
2015 204 268 444 749 3227 4892 1.25
2020 201 285 404 1035 3660 5585 1.44
2025 201 253 422 931 4538 6345 1.66
2035 190 257 332 881 5161 6821 1.91
2050 150 268 414 970 4567 6369 2
only be considered for clinical trials.10 Apart from Malta and Latvia, 
all EU-member states offer some form of financial reimbursement 
to any of these classes of anti-dementia drugs.
In recent years, strategies on dementia care have also been 
developed in parallel with pharmacotherapeutic research since 
caregivers suffer from high rates of physical and mental disorders 
including anxiety and depression.11 Caregivers are also generally 
excluded in providing their views on the effectiveness of anti-
dementia pharmacotherapy in ameliorating the symptoms as 
most research is focused on the disease model. A recent review 
study found that not one of the 63 papers (listed in medical 
databases) reporting on the effectiveness of drug treatments 
included the carer perspective.12 Indeed, the carer perspective 
becomes important in assessing the effectiveness of a particular 
anti-dementia pharmacotherapeutic regimen in enhancing 
the quality of life and assessing caregiver burden.13 The input 
of carers would also be instrumental in providing qualitative 
information that should aid medical professionals to adjust 
therapy ensuring better pharmacotherapeutic outcomes.
Hospital-based pharmacotherapeutic 
management
In Malta, no research has yet been carried out on the use of 
pharmacotherapeutic agents in treating the various symptoms 
observed in dementia. In order to have an indication on the use of 
anti-dementia drugs in a local hospital-based clinic, a small scale 
exercise involving ten persons with dementia was conducted 
in October 2008. Also involved were seventeen caregivers, 
the latter comprising five spouse carers (two husbands and 
three wives), nine children (eight daughters and one son) and 
three daughter-in-laws. The sample of potential caregivers was 
selected from the Zammit Clapp Hospital Memory Clinic and 
was subsequently interviewed by a member of the research 
team. All participants had to be caring for a relative who had a 
formal diagnosis of dementia, who was attending the Memory 
Clinic, who continued to live in the community and who was 
over 65 years of age. The medical history of individuals with 
dementia was analysed for parameters including Mini Mental 
Scale Examination (MMSE) scores (which classify dementia 
into mild, moderate and severe), date of first attendance to 
the Memory Clinic, date of diagnosis, medical conditions 
besides dementia and pharmacotherapy. Ethical approval was 
obtained from three sources prior to conducting the interviews 
with caregivers. These included the University of Stirling (UK) 
Ethics Committee, the University of Malta Research Ethics 
Committee and the Malta Health Department. All relatives 
participating in the study received a written information sheet 
prior to consenting to participate and this was also discussed 
verbally prior to obtaining written consent.
The results showed that more than half of the persons with 
dementia participating in the exercise had the moderate form 
of dementia in which there is clear impairment of cognitive 
function that may require continuous supervision (Figure 1). The 
rest of the patients had mild or questionably significant deficits in 
which the person with dementia continues to function normally 
with support and assistance. No patient had a Mini Mental 
State Examination score of less than 10 denoting the severe 
form of the condition which requires continuous supervision 
and assistance in their Activities of Daily Living (ADL). Table 2 
shows the time intervals from when the person with dementia 
visited the Memory Clinic for the first time until diagnosis of 
dementia and initiation of treatment was performed. The mean 
number of days elapsed from first visit to diagnosis was that of 
41.3±19.3 (mean±SEM) days. The majority of patients had their 
diagnosis of dementia during their first visit to the clinic. The 
mean number of days elapsed from diagnosis till the initiation 
of treatment was that of 69.4±42.3 (mean±SEM) days with 
most patients prescribed anti-dementia medication on the day 
of diagnosis. The mean total number of elapsed days from the 
patient first visit to the clinic till the initiation of treatment was 
of 108.3±34.9 (mean±SEM) days. Figure 2 shows the percentage 
of other pathological disorders in conjunction with dementia 
(taken as 100% to signify that all patients participating in this 
exercise had dementia). Most of the patients had depression 
and a significant number had diabetes, hypertension and 
hypecholesterolaemia. Other less common comorbidities 
included gout, anxiety, hearing loss and previous surgical 
interventions prior to dementia diagnosis. Figure 3a shows the 
amount of drugs prescribed for every person with dementia. The 
total number of drugs prescribed was 59 giving an average of 
5.9 drugs per patient. The majority of patients were prescribed 
four or more drugs. All persons with dementia, except one, 
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were prescribed anti-dementia pharmacotherapy which mainly 
consisted of the acetylcholinesterase inhibitor galantamine 
and the partial NMDA receptor antagonist memantine. A total 
of fifty drugs were used to control other coexisting medical 
conditions with the majority being cardiovascular agents 
followed by antidiabetics, antidepressants and lipid lowering 
agents. Supplements and vitamins were prescribed in a number 
of cases whereas antipsychotics were used in one of the patients 
(Figure 3b).
The qualitative interviews with seventeen caregivers showed 
a lack of perceived support by carers when caring for a person 
with dementia. The majority of participants mentioned the lack 
of professional healthcare services specifically aimed for patients 
with cognitive difficulties. Most importantly, caregivers reported 
the significant financial costs involved in the purchase of anti-
dementia medication since dementia is not included among the 
conditions listed in the Fifth Schedule of the Malta Social Security 
Act. It was also observed that relatives are ambivalent as to the 
effectiveness of these drugs but they were unwilling to discontinue 
treatment in case it made caregiving more difficult or that the 
symptoms will worsen. This is reported in detail elsewhere.14
Discussion
Dementia is an ever-growing condition that is associated 
with significant social, physical, psychological and psychiatric 
disability not only in individuals diagnosed with the illness 
but also in caregivers and family members. Up until recently, 
there was no effective pharmacotherapeutic intervention to 
manage the cognitive symptoms associated with dementia.10 
Although the benefits of current treatments are deemed to be 
modest in that they do not halt the disease progression, they 
represent a major step forward in the clinical management of 
these patients.12 Although the presented small scale exercise 
Table 2: Time intervals from first visit to initial diagnosis and treatment for each person with dementia (PWD) 
participating in the exercise (* signifies diagnosis of dementia during the first visit at the Memory Clinic, ** signifies 
initiation of treatment on the same day of dementia diagnosis).
PWD Days elapsed from first 
visit to diagnosis
Days elapsed from 
diagnosis to initiation 
of treatment
Total number of days 
from first visit to 
initiation of treatment
1 111 0** 111
2 n/a n/a n/a
3 0* 306 306
4 90 0** 90
5 26 0** 26
6 0* 77 77
7 0* 103 103
8 0* n/a n/a
9 145 0** 145
10 0* n/a n/a
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Figure 1: Minimental State Examination 
(MMSE) scores for each person with dementia 
(PWD) participating in the exercise together with 
interpretation of the scores according to Folstein et al.29
Score Degree of 
impairment
Day-to-day functioning
25 to 30 Questionably 
significant
May have clinically 
significant but mild deficits. 
Likely to affect only most 
demanding activities of daily 
living
20 to 25 Mild Significant effect. May 
require some supervision, 
support and assistance
10 to 20 Moderate Clear impairment. May 
require 24-hour supervision
0 to 10 Severe Marked impairment. 
Likely to require 24-hour 
supervision and assistance 
with ADL
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has its limitations in terms of the number of subjects involved, 
the general trend observed indicate that at the Zammit Clapp 
Hospital Memory Clinic, patients are mostly diagnosed early 
upon their first clinical appointment, are mostly managed with 
acetylcholinesterase inhibitors and usually suffer from other 
comorbities which may or may not be related to dementia. 
Furthermore, the overall feeling of caregivers and family 
members is that they are being left out from decisions on 
pharmacotherapy prescribed for patients with dementia under 
their care.
Various studies suggest that pharmacotherapeutic 
intervention with anti-dementia medication early in the disease 
process may slow down the disease progression and thus 
improve the quality of life for both patient and caregivers.15 
Although this exercise did not examine the time lapse prior 
to seeking clinical advice following the emergence of the first 
symptoms, it is clear that most of the patients did not seek 
medical intervention early and thus the majority were in the 
moderate stages of the disease. Reasons for such delay may 
include caregiver’s lack of knowledge or reluctance to seek 
help, and patient, family, and physician-related factors.16 In 
participating patients, pharmacotherapeutic dementia-related 
intervention consisted of the use of both acetylcholinesterase 
inhibitors and glutamatergic-system modifiers. Whether the use 
of these agents had any significant effect on delaying the disease 
progression or controlling the behavioural symptoms of our 
patients is unclear and was beyond the scope of this exercise.
Acetylcholinesterase inhibitors were the first pharmacological 
treatment approved for symptomatic treatment of AD. These 
drugs have been found to stabilise the cognitive decline for up 
to 3-6 months.17,18 Memantine, the only glutamatergic system 
modifier approved for the treatment of AD, was also reported 
to improve dementia symptoms by reducing the rate of clinical 
deterioration among patients with moderate to severe AD.9,19 
Currently there is a strong debate on the cost effectiveness of the 
Table 3. Characteristics of pharmacotherapeutic agents used in the management of Alzheimer’s disease (AChEI: 
acetylcholinesterase inhibitor, AD: Alzheimer’s disease, nAChRs: nicotinic acetylcholine receptors, NMDA: 
N-methyl-D-aspartate).28
Medication
Pharmacological 
class
Mode of action Recommended use
Potential  
adverse effects
Donepezil 
hydrochloride 
(Aricept®)
AChEI
Block 
acetylcholinesterase 
enzyme
Mild-to-moderate AD
Anorexia, diarrhoea, 
dreams, fatigue, 
insomnia, muscle 
cramps, nausea, 
vomiting, weight loss
Rivastigmine 
tartrate (Exelon®)
AChEI
Block both acetyl- 
and butyryl- 
cholinesterase 
enzymes
Mild-to-moderate AD
Anorexia, diarrhoea, 
nausea, vomiting, 
weight loss
Galantamine 
hydrobromide 
(Reminyl®)
AChEI
Block 
acetylcholinesterase 
enzyme. Allosterically 
stimulates nAChRs 
Mild-t0-moderate AD
Anorexia, nausea, 
vomiting, weight loss
Memantine 
hydrochloride 
(Axura®, Ebixa®)
Glutamatergic system 
modifier
Partial NMDA 
receptor antagonist
Moderate-to-severe 
AD
Agitation, 
constipation, 
dizziness, 
hallucinations, 
headache, insomnia
Dementia
Depression
Diabetes
Hypertension
Hyper-
cholesterolaemia
Percentage of PWD
0 20 40 60 80 100
Figure 2: Most common comorbid disorders in PWD 
participating in the exercise.
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This prescribing behaviour is in concordance with current 
recommendations denoting that early initiation of therapy is 
associated with greater long-term benefits.20 
A significant number of participating patients were 
diagnosed with depressive illness possibly indicating a high 
prevalence rate of depression in patients with dementia. This 
was also reflected by the significant use of antidepressants as part 
of the overall prescribed treatment regimen. Epidemiological 
studies show a possible pathological association between the 
two conditions, with depression possibly acting as a prodromal 
sign or early symptom of AD.21 Due to the limited number 
of patients participating in this exercise, it was not possible 
to investigate any link between depression and dementia 
although this would be an interesting research area for future 
consideration. The same is also valid with the other main 
pathologies observed. Although cardiovascular disease, diabetes 
and hypercholesterolaemia are risk factors in vascular dementia, 
these conditions are also prevalent in old age. 
The use of multiple medication (polypharmacy) in the 
elderly has always been regarded as a complex issue in 
pharmaco-geriatric management. Although polypharmacy may 
be the only choice in some individuals, multiple medication use 
may increase the risk of non-compliance, medication error and 
potentially adverse drug interactions.22 Prescribing for elderly 
patients with dementia proves to be even more challenging 
due to the changing needs that accompany cognitive decline 
and related behavioural symptoms.23 Furthermore, more 
medications may be indicated in patients with dementia due to 
the presence of other pathologies which are common in old age.24 
Our data indicated that, on average, each person with dementia 
was prescribed with more than five different medications for the 
management of dementia and other comorbidities. This finding 
raises important clinical concerns, especially for individuals 
who still live in the community, in some cases on their own. 
Furthermore, because the use of polypharmacy increases the 
risk of falls, prescribing unnecessary medication may further 
enhance institutionalisation. Polypharmacy is also associated 
with increased risk of adverse drug-drug interactions which can 
have potential life-threatening consequences in older adults. 
This is especially critical in patients with dementia who are 
cognitively impaired and therefore not be able to explain or self 
report the symptoms. Interestingly, only one drug (lorazepam) 
was found to be part of the Beers Criteria,25 a list of medications 
that are generally considered to be inappropriate when given to 
the elderly. No potentially serious drug-drug interactions were 
observed. In line with guidelines issued by NICE,10 prescription 
of antipsychotic drugs was only present in one participating 
patient attending the Memory Clinic. Recent data shows that 
the use of these drugs in persons with dementia is associated 
with an increase in the risk of fatality.26
Studies including the views and experiences of caregivers 
on the effectiveness of anti-dementia drugs are lacking with a 
major focus directed towards conventional scientific evidence 
which is mostly relevant to clinicians and research scientists. 
Figure 3: Number of PWD on polypharmacy (a) and 
total number of drugs prescribed to all patients as per 
drug mode of action or therapeutic class (b).
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widespread use of these drugs for the various stages of AD. The 
National Institute of Clinical Excellence (NICE) recommends the 
use of acetylcholinesterase inhibitors in the moderate stages of 
the disease with the use of memantine reserved only for clinical 
trials.10 This decision was widely criticised by the Royal College 
of Psychiatrists, the British Geriatric Society and the Royal 
College of Nursing as well as by various EU-based dementia 
societies. In Malta, no such recommendations exist and both 
classes of drugs can be prescribed by general practioners and 
specialists.  Interestingly, the trend observed indicated that half 
of the participating patients were recommended with the use 
of anti-dementia drugs upon diagnosis during their first visit at 
the Memory Clinic, irrespective of the severity of the condition. 
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This lack of caregiver perspective was apparent in our qualitative 
assessment of the participating subjects. Caregivers were mostly 
concerned with the lack of support from the central health 
authorities in caring for their relatives. The greatest concern 
is the lack of financial assistance in purchasing anti-dementia 
medication which, in some cases, can take up a third of the 
person with dementia pension. Together with Latvia, Malta is 
the only country where the health authorities do not offer any 
form of financial support in accessing these drugs.27 Even though 
some caregivers interviewed were unsure of the efficacy of anti-
dementia medication in slowing the disease progression, they 
were unwilling to stop treatment.
Conclusion
Although more research is needed, using a larger sample 
number, the trends observed highlight the need for a 
nationwide strategy that includes the various aspects involved 
in pharmacological and non-pharmacological management 
of dementia. Such strategy should include the views of policy 
makers, healthcare professionals as well as patients and their 
caregivers with the aim of designing and implementing a series 
of recommendations that that should enhance high-quality 
dementia care in Malta.
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Review Article
Pulmonary rehabilitation: 
insight into current trends 
Anabel Sciriha, Stephen Montefort
Abstract
Pulmonary rehabilitation is a widely accepted therapeutic 
tool used to improve the quality of life and functional capacity of 
individuals with chronic lung disease. It is a multidisciplinary, 
comprehensive program designed to optimise autonomy and 
physical performance in patients with chronic respiratory 
impairment. There is sufficient evidence to support the use 
of pulmonary rehabilitation for a subset of patients and to 
indicate that it can improve exercise tolerance and symptoms 
of dyspnoea, as well as enhance health-related quality of life of 
patients with COPD and other respiratory conditions. According 
to projections in the Global Burden of Disease Study, COPD will 
be the fifth leading cause of disability-adjusted-life-year loss 
worldwide in 2020.
The goal of pulmonary rehabilitation is to help the individual 
achieve the highest level of independent functioning by 
improving pulmonary function, increasing exercise endurance 
and exercise work capacity, reducing dyspnoea and normalising 
blood gases. 
Locally, no pulmonary rehabilitation service as described by 
respiratory societies is offered. Therefore, this paper will look 
into the current research focusing on future recommendations 
for this service in the international setting with an aim of 
implementing this into the local health care system.
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Introduction
Rehabilitation is the restoration of individuals to the fullest 
medical, mental, emotional, social and vocational potential the 
individual is capable of. The basic premise of all rehabilitation 
is that it is possible to effect positive change under the poorest 
circumstances imaginable and that no effect of illness save for 
death is absolute.1
Pulmonary rehabilitation is defined as a program for 
people who have chronic lung disease.2 Its primary goal is to 
enable people to achieve and maintain their maximum level 
of independence and functioning. Although most pulmonary 
rehabilitation programs focus on people who have chronic 
obstructive pulmonary disease,2 people with other types of lung 
disease may benefit as well. The most successful rehabilitation 
programs are those in which services are provided by a 
physiotherapist, nurse, doctor, psychologist or social worker, 
and a dietitian working as the pulmonary rehabilitation team 
to coordinate complex medical services.3 
Optimal length of the rehabilitation phase
Despite the increasing propagation of the efficacy of 
pulmonary rehabilitation, there is no definitive proposal for 
the best training strategy2-4 with variances in the duration and 
frequency.5,6 Significant gains in exercise tolerance, dyspnoea, 
and quality of life have been observed following rehabilitation 
programs as short as 10 days7 and others as long as 18 months8 
with gains in exercise tolerance reported to be greater in 
the latter.9 Two randomised trials compared 3 months and 
18 months of low-intensity exercise training. The longer 
intervention led to 6% increase in the 6 minute walk distance, 
12% reduction in self-reported disability and faster completion 
of stair climbing and overhead tasks.10 No differences though 
were seen in pulmonary function studies between groups, after 
training. The investigators concluded that the benefits achieved 
after short-term pulmonary rehabilitation began to decay once 
the intervention was terminated, despite encouragement to 
continue participation in a home-based or community-based 
programme. On the other hand, Foy et al 11 showed that only 
male patients achieved greater gains in Chronic Respiratory 
Disease Questionnaire scores following the 18-month program 
(compared to 3 months). In fact, more favourable scores than 
those in the short-term group were reported for dyspnoea, 
fatigue, emotional function and task mastery. 
In a 2005 published prospective trial12 involving seven 
outpatient programmes, patients achieved significant gains 
in exercise tolerance (6 minute walk distance), dyspnoea and 
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health status (Medical Outcomes Study 36-item Short Form and 
quality-of-life index) after 12 weeks of pulmonary rehabilitation. 
Following an additional 12 weeks of rehabilitation, exercise 
tolerance, but not health status or dyspnoea, outcomes 
improved further, suggesting that programme duration may 
not impact all outcomes equally. Also, in support of longer term 
exercise training, 6-month outpatient pulmonary rehabilitation 
programmes composed of moderate-to-high-intensity aerobic 
and strength exercise training led to significant improvements 
in exercise performance and quality of life.13 Although this study 
did not compare the 6-month programme with a shorter one, 
the benefits gained following the 6-month training program 
persisted 18 months after the completion of rehabilitation. 
Severe COPD patients were also found to achieve greater 
improvements in treadmill endurance, incremental shuttle walk 
distance, and quality of life following a 7-week outpatient pulmonary 
rehabilitation programme compared with an identical program of 
only 4 weeks duration. However, patients who underwent the 
4-week programme were not reassessed at the 7-week time point 
to enable the direct comparison of outcomes.9
Overall, although some studies suggest that the duration 
of the pulmonary rehabilitation programme impacts exercise 
tolerance improvement, it is less clear that other outcomes such 
as health status or dyspnoea are similarly affected by programme 
duration. Randomised controlled trials have shown that short-
term pulmonary rehabilitation (4 to 12 weeks) can reduce the 
number of hospitalisations, improve quality of life, reduce 
respiratory symptoms, improve exercise tolerance, increase 
self-efficacy, and improve the ability to perform activities of 
daily living. However, only a few studies have looked at the 
benefits of long-term (12 weeks or more) supervised pulmonary 
rehabilitation (Table 1).
It has not been established to what degree the benefits 
of short-term pulmonary rehabilitation diminish over time, 
how long these benefits persist with continued supervised 
intervention, or the optimal nature of long-term pulmonary 
rehabilitation intervention. The confounding effects of multiple 
study designs including varying durations of exercise, education, 
breathing retraining, and home exercise interventions have 
hindered solid conclusions about these issues. 
Rehabilitation in the acute and chronic phase
Acute exacerbations of COPD represent a major burden 
for patients and health care systems.13,14 They are a common 
reason for hospital admissions and severely affect health-
related quality of life15 and prognosis.16 Mortality rates during 
hospitalisations are around 10%17 and during the following 
year hospitalisation may be as high as 40%. From the health 
care provider’s perspective, COPD is resource consuming18 and 
about 10% of COPD patients suffering from acute exacerbations 
account for over 70 percent of costs caused by COPD, primarily 
due to emergency visits and hospitalisations. 
Position papers of the American College of Physicians and 
American College of Chest Physicians provide recommendations 
on the management of acute exacerbations. However, 
no recommendations on how future exacerbations and 
hospitalisations could be prevented are indicated, despite 
this being one of the main goals of COPD management. One 
solution that has been adopted in clinical practice is to provide 
rehabilitative care after treatment of acute exacerbation 
including physical exercise, patient education focusing on self-
management strategies and psychosocial support. 
The rationale to offer rehabilitation in patients recently 
treated for acute exacerbation is to enhance quality of life, as 
in stable COPD patients14 and modify factors associated with 
increased risk for post-exacerbation morbidity and mortality. 
Patients with frequent exacerbations have more pronounced 
skeletal muscle weakness and a more limited six minute walking 
distance, which is in turn a risk factor for exacerbations and 
mortality. Thus, respiratory rehabilitation may have the potential 
to reduce hospital admissions by improving exercise capacity. It is 
surprising that research on the effects of respiratory rehabilitation 
in patients after acute exacerbations, is very scant. 
Randomised controlled trials evaluating the effects of 
pulmonary rehabilitation after hospitalisation for acute 
exacerbations of COPD,19 report improvements in outcome 
measures at three months after hospital discharge with significant 
improvements in walking distance (p=0.0002), health status 
scores (p=0.002), all four domains of the Chronic Respiratory 
Questionnaire (dyspnoea, p=0.003; fatigue, p=0.004; emotion, 
p=0.008; mastery of tasks, p<0.001). Therefore, this trend 
showed that early intervention with pulmonary rehabilitation 
after a hospital admission for acute exacerbations of COPD is 
safe and leads to statistically and clinically significant short-term 
improvements in exercise capacity and health status.19
Compared to rehabilitation during stable periods, the effects 
of rehabilitation tend to be larger after acute exacerbations. 
Studies looking at the acute phase are relatively small in 
sample size, therefore there is the tendency to overestimate 
the effect of an intervention compared to large trials. Also, 
methodological limitations were found and one cannot exclude 
that the estimates provided by the meta-analyses represent 
overestimations of the effect of respiratory rehabilitation after 
acute exacerbation. Therefore, larger trials seem justified to 
challenge the data available. 
When conducting studies post acute exacerbations, 
recruitment of patients may be difficult because not all of them 
may want to be randomly allocated to respiratory rehabilitation 
or conventional care, in a situation of poor health status. It 
must also be taken into consideration that exercise capacity is 
particularly low after acute exacerbations, and therefore the 
exercise programme should be designed carefully. Strength 
exercise and tolerable whole body exercise modalities such 
as interval exercise may be particularly suitable for these 
patients.19 Rehabilitation may not only reduce the number of 
acute exacerbations, but also their severity. Patients may learn 
to notice imminent exacerbations and seek medical attention 
earlier leading to a shift from inpatient to the less costly 
outpatient treatment of acute exacerbations. The significant 
reduction in hospital readmissions is suggestive of a beneficial 
cost-benefit balance. 
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Pulmonary rehabilitation in respiratory 
conditions other than COPD
Although there are some studies stretching the beneficial 
role of pulmonary rehabilitation to other respiratory diseases, 
the reported evidence is highest for COPD.19 
It is believed that pulmonary rehabilitation has positive 
effects in a large range of chronic pulmonary conditions 
including asthma.20,21 The scientific rationale for providing 
pulmonary rehabilitation to patients with non-COPD diagnoses 
is the same as for COPD. As in COPD, persons with other 
forms of chronic respiratory disease commonly experience 
deconditioning and exercise intolerance, disabling symptoms of 
dyspnoea and fatigue, impaired health status and quality of life, 
systemic inflammation, nutritional impairments, and/or muscle 
dysfunction (related to deconditioning, loss of fat-free mass, 
and/or corticosteroid use) that collectively impair functional 
status along with abnormalities of pulmonary function.20 
Modification of the relative emphasis on the core programme 
components and overall programme content may be required 
to maintain patient safety and to meet individual patient 
needs and goals which may differ from the standard goals for 
COPD.2 Disease-appropriate and age-appropriate tools for the 
assessment of exercise capacity, health status, and quality of 
life should be utilised, and efforts must be made to integrate 
topics relating to non-COPD diagnoses in situations in which the 
patient group is composed predominantly of COPD patients.
Although most of the studies published to date, which 
investigate the outcomes of pulmonary rehabilitation for 
disorders other than COPD are uncontrolled trials or case 
series, randomized clinical trials are beginning to emerge22,23 
with the strength of existing evidence supporting pulmonary 
rehabilitation varying across the different diseases.
Importance of nutritional 
and psychological care
The need of a multidisciplinary programme also includes 
nutritional and psychological assessment. Nutritional depletion 
is commonly found in COPD patients and this affects both the 
respiratory and skeletal muscle function, contributing to an 
increased morbidity and mortality.24 Schols and colleagues 
Duration of Pulmonary Rehabilitation
Study/ year Study type Country/Setting No of Patients Outcomes/results
Troosters et al. 2000 RCT: 6 vs 18 months vs usual 
care
Belgium/OP 100
Pulmonary function; exercise 
capacity; muscle strength; QOL 
Walking distance (p<0.05);exercise 
capacity (p<0.02);  no significant 
effects of training programme on PF 
measures vs usual care; improved 
quadriceps strength (p<0.05) and 
QOL (p< 0.001)
Foy et al. 2001
RCT: short- vs  
long-term
PRP
United States/OP 140
Four domains of CRQ. Significant 
changes in short vs long term in all 
domains
Green et al. 2001 RCT: single-blind; short vs long-term 
PRP
UK/OP 44
Endurance; HRQL CRDQ (p<0.011); 
dyspnoea (p<0.021), emotion 
(p<0.003), mastery (p<0.027)
Berry et al. 2003
 
RCT: single-blind; 
short vs long-term 
PRP United States/OP 140
Physical function and disability; 
pulmonary function
Disability: p<0.016 long- vs short-
term
Physical function: increased walk 
distance (p< 0.03 long term);
stair climb time (p< 0.05)
Pulmonary function: NS
Sewell et al. 2006
RCT conventional 
seven-week 
supervised program 
(n=50) or to a four-
week supervised 
programme (n=50).
100
At seven-week follow-up, patients 
in the four-week program attained 
higher submaximal exercise 
performance times for a mean 
difference 124 seconds (p=0.024).
Table 1: Reported durations and outcomes of pulmonary rehabilitation programmes.  (RCT: randomized 
clinical trial; OP: outpatient, PRP: pulmonary rehabilitation programme, QOL: quality of life; 
PF: pulmonary function; NS: not significant)
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found that patients who increased their weight by more than 
2 kg had a significantly better survival, independently of 
their initial body mass index.25 Because of the morbidity and 
mortality associated with underweight COPD patients, it is 
therefore being recommended that interventions should be 
extended to prevention and early treatment of weight loss, 
before patients become extremely wasted, and therefore put 
more emphasis on dietary change than on medically prescribed 
supplementation.2,17
The psychological input is also required as patients with 
chronic respiratory diseases have an increased risk for anxiety, 
depression, and other mental health disorders26,27 leading to 
frustration with poor health and an inability to participate 
in activities which can present as irritability, and a hostile 
attitude toward others. In the later stages of respiratory 
disease, progressive feelings of hopelessness and inability to 
cope often occur. When psychologic support is provided within 
the rehabilitation setting, one will be able to help facilitate the 
adjustment process by encouraging adaptive thoughts and 
behaviours as well as helping patients to reduce any negative 
emotions present.
As is documented in a review of randomized studies, 
Griffiths and colleagues reported reduced symptoms of anxiety 
and depression following a 6-week pulmonary rehabilitation 
program, with symptoms of depression remaining significantly 
reduced at the 12-month follow-up.28 Also, Emery and 
colleagues29 found reduced anxiety and improved cognitive 
function following a 10-week pulmonary rehabilitation 
intervention. 
Recommendations and conclusion
With a constant increase in COPD patients, and this disease 
ranking 4th for mortality and morbidity rates, more research in 
this field is required to further look into the above discussed 
issues in order to help the local development of the best 
pulmonary rehabilitation service for the treatment of respiratory 
patients. Coordination of services is very important, especially 
during episodes of exacerbation, which are characterized with 
high morbidity and a marked increase in use of health care 
resources.
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Case Report
Management of inflammatory dentigerous 
cysts in children: report of two cases
Erica Scerri, Alexander Azzopardi
Abstract
Inflammatory dentigerous cysts are usually associated with a 
carious or non-vital primary tooth. Consequently they are found 
in children with a mixed dentition. This report describes two 
cases of inflammatory dentigerous cysts associated with the lower 
second premolars. Both cases were treated by marsupialisation 
of the cysts that eventually led to the spontaneous eruption of 
the premolars. 
Introduction 
Odontogenic cysts in children are rare with only 1% of the 
radicular cysts and 9% of the dentigerous cysts occurring in 
the first decade of life.1 Dentigerous cysts are developmental in 
origin and are usually associated with impacted teeth or teeth 
that erupt late. Inflammatory dentigerous cysts are associated 
with the roots of carious or non-vital primary teeth and the 
crowns of unerupted permanent successors. Consequently, 
they can only be found in the mixed dentition. A possible 
pathogenesis of these cysts is periapical inflammation from a 
non-vital deciduous tooth spreading to involve the follicle of 
the unerupted permanent successor tooth. The inflammatory 
exudate causes the reduced enamel epithelium to separate 
from the enamel leading to the formation of a dentigerous 
cyst.2 Several authors2-4 have reported cases of dentigerous cysts 
associated with an infected predecessor tooth. The following two 
case reports show the successful management of two such cases 
referred from general dental practice.
Case report 1
A healthy 7-year old boy was referred to the Dental 
Department of St Luke’s Hospital, Malta in May 2005 following 
extraction of a carious lower right second deciduous molar 
(85) in General Dental Practice. A hard swelling in the lower 
right buccal sulcus in the premolar region did not subside 
even following antibiotics and was still present one week after 
the extraction. A panoramic radiograph (Figure 1) showed 
a large unilocular radiolucent lesion surrounding the crown 
of the lower right second premolar with displacement of the 
lower right premolar crowns towards the lower border of the 
mandible. Marsupialisation of the cyst was carried out under 
local anaesthesia, and a specimen was sent for histological 
examination. The patient was provided with an acrylic plate 
with a plug and was instructed to irrigate the cyst cavity with a 
chlorhexidine mouthwash. The histology report was that of a 
radicular cyst. The patient was reviewed every month to reduce 
the depth of the acrylic plug. Radiologic examination showed 
the cyst to be reducing in size and by August 2005, a panoramic 
radiograph showed the lower right premolars to be migrating 
occlusally. In October 2005, the cyst opening had closed 
completely and it was decided to re-open the cyst cavity. This 
was carried out under local anaesthesia and cold curing acrylic 
was used to build-up the plug on the lower plate. Two months 
later, radiologic examination showed that the cyst cavity was 
decompressing and the lower right premolars were erupting into 
position (Figure 2). By January 2007 the lower right premolars 
were clinically visible and by July 2007 they were fully erupted. 
The patient is still being reviewed at the orthodontic clinic of 
Mater Dei Hospital, waiting for the permanent dentition to be 
established.
Erica Scerri* BChD, MSc
Department of Dental Surgery
Mater Dei Hospital, Malta
E-mail: ericascerri@onvol.net
Alexander Azzopardi BChD, PhD
Department of Dental Surgery, 
Mater Dei Hospital, Malta
Keywords
Dentigerous cysts, Children, Inflammatory, Treatment
* corresponding author
Figure 1: Inflammatory dentigerous cyst involving the 
mandibular right second premolar.
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Case report 2
In November 2006, a healthy 10-year old boy presented 
at the Dental Department with a firm swelling associated with 
a grossly decayed lower left second deciduous molar. The 
lower left first deciduous molar and the lower right deciduous 
molars had been previously extracted. A panoramic radiograph 
(Figure 3) revealed a well defined unilocular radiolucency 
embedding the crown of the lower left second premolar which 
was displaced apically. The carious lower left second deciduous 
molar was extracted and cyst marsupialisation was carried out 
under general anaesthesia. The cavity was packed with Bipp 
gauze during the first two weeks post-operation. The patient 
was then provided with a removable lower space maintainer 
with an acrylic plug in the cyst region to maintain the opening 
of the cyst patent. The patient was instructed to rinse with a 
chlorhexidine mouthwash and was reviewed every two weeks to 
reduce the height of the plug. The lower left premolars erupted 
spontaneously as the cyst decompressed. By May 2007 the lower 
left first premolar had started to erupt and the lower left second 
premolar was clinically visible by July 2007. The acrylic plug 
was removed completely but the patient was instructed to keep 
on wearing the lower space maintainer to prevent mesial tilting 
of the lower first molars. In April 2008, a panoramic radiograph 
(Figure 4) showed that the radiolucent lesion in the lower left 
premolar region had resolved completely. The lower left second 
premolar was however impacted beneath the contact point of 
the lower left first molar. The patient also had a developing Class 
III malocclusion and impacted upper second premolars and was 
therefore referred for orthodontic treatment. He is still being 
followed up at the orthodontic clinic of Mater Dei Hospital.
Discussion
There have been 20 reported cases of dentigerous cysts in 
Maltese children in approximately the first decade of life from 
1961 till 2006. They are more common in boys and more likely 
to occur in the lower jaw (unpublished data compiled by Prof. 
G. E. Camilleri). Both cases described here were associated with 
the lower second premolar teeth and both patients were males. 
The radiographic appearance of the cystic lesion in both cases 
was that of a unilocular, well defined radiolucency enclosing the 
crown of the second premolar tooth suggesting the diagnosis of 
a dentigerous cyst. However, since dentigerous cysts are usually 
associated with impacted teeth or teeth that erupt late, the 
radiographic signs, in both cases, did not support the diagnosis 
of a developmental dentigerous cyst. In the first case presented 
here, there was still no root formation of the second premolar 
and therefore it was unlikely that tooth eruption had started. 
In the second case, although root formation had started, there 
was nothing to suggest that the second premolar might have 
been impacted. Therefore it was unlikely that the pathogenesis 
of both cystic lesions was that of a dentigerous cyst which is 
developmental in origin. On the other hand, there appeared to 
be a definite correlation between the cystic lesion and periapical 
pathology from the overlying carious predecessor tooth especially 
in the second case were the roots of the carious deciduous second 
molar could be seen touching the cyst wall. This suggested 
that the cystic lesions were inflammatory dentigerous cysts. A 
specimen was sent for histological examination in the first case 
only and although the histopathological report came back as 
a radicular cyst it is histologically very difficult to distinguish 
between inflammatory dentigerous cysts and radicular cysts2 
and radicular cysts associated with deciduous teeth are very 
rare.5 Unfortunately a specimen was not sent for histology in the 
second case. Therefore, a diagnosis of the cystic lesion in this 
case was not possible. However it is worth noting that a biopsy 
should always be taken to exclude odontogenic tumours and 
other cystic lesions such as the odontogenic keratocyst. These 
lesions may present in a similar way but would necessitate more 
aggressive treatment.
Figure 2: Inflammatory dentigerous cyst decompressing 
and lower right premolars erupting into the dental arch. 
Figure 3: Cystic lesion involving the lower left second 
premolar. The roots of the grossly carious lower left second 
deciduous molar were in contact with the cyst wall.
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Dentigerous cysts in adults are usually treated by surgical 
enucleation and extraction of the associated tooth affected by the 
cyst. In the case of small cysts, enucleation and preservation of 
the involved tooth is sometimes advocated in younger patients. 
Larger cysts are initially reduced in size by marsupialization 
followed by surgical enucleation at a later stage.6 A more 
conservative approach has been used in our two cases of 
inflammatory dentigerous cysts because of the young age of the 
patients. Following the removal of the carious deciduous teeth, 
decompression of the cysts was carried out and the opening 
was then kept patent with the use of an acrylic plug to allow the 
cyst to shrink and at the same time allow bone regeneration to 
occur. This eventually resulted in the spontaneous eruption of 
the premolars in both cases and has prevented the loss of any 
permanent teeth or damage to any of the adjacent structures.
Figure 4: Lower left first and second 
premolars fully erupted
The above two cases highlight the importance of preventive 
measures and proper management of carious deciduous teeth to 
avoid these complications. Regular follow-up of the deciduous 
dentition is of the utmost importance because an inflammatory 
dentigerous cyst can attain a considerable size before the patient 
becomes aware of it, this usually being asymptomatic. Simple 
management of inflammatory dentigerous cysts usually results 
in a satisfactory outcome without loss of teeth. The prognosis is 
much better in children because of the greater eruptive potential 
of teeth with open apices and the greater regenerative potential 
of young bone. 
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Case Report
A rare cause of hypoglycaemia
Robert Sciberras
Abstract
This paper describes a case study concerning a young man on 
treatment for psychiatric illness who developed severe episodes 
of hypoglycaemia. After several investigations, lithium therapy 
was implicated. Stopping this treatment resulted in the patient 
being relieved of these episodes.
A rare cause of hypoglycaemia
F.A. is a 36 year old male health care worker with a long-
standing history of psychiatric illnesses and repeated admissions 
to the Psychiatric Short-Stay Ward. The depressive illness was 
precipitated by an accident in a previous work-place. Other past 
history included hypertension of 4 years duration and spinal 
surgery for a prolapsed disc in 2006.
The patient is married to a diabetic lady, who is on gliclazide 
and metformin. She monitors her own blood glucose at home 
using a glucose meter.
F.A. was referred in October 2008 complaining of recurrent 
hypoglycamic attacks occurring approximately every 2 days 
for the past 4 weeks. The low glucose levels ranging between 
2.2mmol/L and 2.7mmol/L were documented by his wife using 
her glucose meter. The hypoglycaemic attacks were typical and 
included excessive sweating, tremors, nausea and at times, 
episodes of confusion. The episodes were relieved by the patient 
ingesting a large bar of chocolate followed by sugary drinks. 
The patient was on clozapine 25mg, ½ tablet three times a 
day, lithium 400mg tabs, 600mg at night, mianserin 10mg, two 
tablets three times a day and paroxetine 20mg two tablets in the 
morning and one tablet in the evening. His blood pressure was 
well controlled with amlodipine 5mg once daily. 
There were no other systemic complaints, and no relevant 
family history. There was no recent change in appetite or weight. 
Examination was unremarkable. Given his work-place and also 
his home situation, surreptitious ingestion of oral hypoglycaemic 
agents was suspected but subsequently eliminated as the 
cause for his attacks. At his place of work he did not have 
access to any hypoglycaemic agents. At home, his wife kept 
her medications under lock and key particularly because the 
couple had two small children. She could also account for all 
her tablets. Psychiatric consultation concerning whether any 
of the psychiatric medications could be causing hypoglycaemia 
proved negative. All investigations including thyroid function 
tests were normal. Serum lithium level was 0.45mmol/L (normal 
range 0.6-1.2mmol/L). The patients did not present a history 
of lithium toxicity.
The patient was admitted to Gozo General Hospital for 
monitoring at the end of October 2008. During admission two 
hypoglycaemic attacks occurred and were witnessed by the 
author. The glucose levels were 2.6mmol/L and 2.7mmol/L 
respectively. The hypoglycaemic attacks had to be aborted 
rapidly by dextrose infusion as the patient became very 
symptomatic, confused and on the point of becoming aggressive. 
Blood tests were taken during the hypoglycaemia: C-Peptide 
level was 5.85ng/ml (normal range is 0.80-4.00ng/ml), insulin 
level was 31.0microU/ml (normal range 2.0-25.0microU/
ml), and proinsulin level was 88pmol/L (normal range is 
6.4-9.4pmol/L). These levels were inappropriately high for a 
patient with hypoglycaemia. 
An insulinoma was suspected and an urgent computerised 
axial tomography of the abdomen was carried out, including 
1.5mm slices at the pancreatic level. This was reported as 
normal.
Meanwhile hypoglycaemic episodes were still occurring in 
spite of continuous dextrose infusion and so the patient was 
started on prednisolone 10mg three times a day. This medication 
put an end to the hypoglycaemic episodes and the patient was 
discharged home pending further investigations. 
An Indium-111 octreotide scintigraphy was performed on the 
17th of December 2008, 4 hours and 24 hours following intravenous 
administration of 160MBq of Octreoscan. Both whole body and 
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SPECT images were acquired. There was no abnormal focus of 
tracer accumulated in the abdomen. Physiological activity was 
seen in liver, spleen and kidneys with intestinal activity evident 
at 24 hours. It was therefore concluded that there was no definite 
evidence of insulinoma. However sensitivity of octreotide 
scintigraphy is in the range of only 50% (see discussion below). 
Surgical consultation resulted in the patient being scheduled 
for exploratory laparotomy which might have included total 
pancreatectomy. At the eleventh hour the surgery was postponed 
due to repeated hypoglycaemic episodes. During one of these 
episodes, blood investigations showed an insulin level of 
22microU/ml (reference range 2.0-25.0microU/ml), C-peptide 
level of 3.64ng/ml (reference range 0.80-4.00ng/ml), and 
proinsulin level of 30.4pmol/L (reference range 6.4-9.4pmol/L). 
The patient was started on diazoxide 50mg, four tablets three 
times a day and discharged home on the 10th of March 2009.
Two days later the patient was admitted urgently to hospital 
complaining of fever of 102 degrees Fahrenheit, severe muscle 
aches and pains, shortness of breath and inability to walk due 
to generalized weakness and stiffness. There was no wheezing 
or rash. His eosinophil count was normal. The symptoms 
had started on initiating diazoxide therapy. A reaction to 
the medication was suspected, the drug withdrawn and all 
symptoms resolved. At this point, lithium therapy started to 
be suspected to be causing the hypoglycaemic episodes in this 
patient. The dose of lithium was reduced to 400mg at night and 
the patient discharged. The rest of the medication was kept at the 
same dose throughout the investigative period. Further visits at 
out-patients revealed that no further episodes of hypoglycaemia 
were occurring since reduction of lithium therapy, in spite of 
the steroids being tailed down. Lithium was eventually reduced 
to 200mg at night and steroids completely stopped on the 27th 
of April 2009. 
On the 15th of May 2009, the patient was admitted to hospital 
for a prolonged fasting test. He was advised not to eat anything 
between 4.00 pm and 8.00 am the following morning. He was 
allowed to drink water only. Blood glucose was monitored every 
hour. There were no low blood glucose readings. At 8.00 am, 
a 75g glucose oral drink was administered. Three hours later 
the patient suffered a symptomatic hypoglycaemic attack with 
blood glucose falling to 2.5mmo/L. The insulin level checked at 
this time was 11.0microU/ml (normal range 2.0-25.0microU/
ml),  C-peptide level was 3.73ng/ml (normal range 0.8-4.00ng/
ml) and proinsulin level was 61.7pmol/L (normal range 
6.4-9.4pmol/L). At this point, therefore, the patient was not 
having spontaneous hypoglyaemic episodes but had a late 
one precipitated by a glucose load. The lithium therapy was 
eventually tailed off by the end of June 2009. 
The prolonged fasting test was repeated on the 23rd of July 
2009. Serum lithium level was <0.10mmol/L (normal range 
0.6-1.5mmol/L), and this confirmed that the patient had indeed 
stopped lithium therapy as instructed. During the fast, the 
patient did not have hypoglycaemic episodes. At 8.00 am, a 75g 
glucose load was administered and the patient was observed for 
six hours later and was allowed to drink water only. Contrary to 
the first prolonged fasting test, the blood glucose estimations 
every 30 minutes were stable and there were no hypoglycaemic 
episodes after the glucose load. 
The patient is still being seen regularly at the hospital out-
patients department. He is well and has had no further problems 
since. A letter to the Medicine Authority has been sent reporting 
the adverse effects caused by lithium and diazoxide. 
Discussion
Lithium salts are used in the prophylaxis and treatment of 
mania, in the prophylaxis of bipolar disorders (manic-depressive 
disorder) and in the prophylaxis of recurrent depression 
(unipolar illness or unipolar depression). A literature search 
for the association of lithium therapy with hypoglycaemia did 
not reveal significant results. Pinelli et al reported neonatal 
hypoglycaemia with maternal lithium therapy, apart from 
Ebstein’s anomaly, cyanosis, rhythm disturbances and thyroid 
dysfunction.1 Shah et al performed five-hour oral glucose 
tests (OGTT) in nine patients receiving lithium therapy and 
in seven control patients.2  During GTT mean nadir serum 
glucose was significantly lower in the lithium-treated patients as 
compared to controls. The study suggested that chronic lithium 
treatment may be associated with symptomatic and biochemical 
hypoglycaemia during OGTT due to a rise in serum cortisol but 
lack of appropriate rise in plasma glucagon concentrations. 
Other hormonal effects were studied by Grof et al.3  In this study, 
lithium treatment resulted in a dramatic reduction in prolactin 
and growth hormone response to insulin hypoglycaemia. The 
reduced prolactin response to hypoglycaemia was also confirmed 
by Grof et al.4  However, other studies tend to contradict 
these findings. In the intact rat, lithium was found to inhibit 
glucose- and tolbutamide-induced insulin release, which in 
turn, causes glucose intolerance and prevents tolbutamide-
induced hypoglycaemia.5 The literature describes one report of a 
patient with lithium toxicity who presented with hypoglycaemia, 
acneform lesions, hypothyroidism and nephrogenic diabetes 
insipidus.6 However the case study presented above was not a 
case of lithium toxicity as was proved by repeated blood tests. 
The first oral glucose tolerance test also suggested a rebound 
type of hypoglycaemia. This could explain the fact that when the 
patient presented originally, his eating chocolate bars to alleviate 
a hypoglycaemic attack was in fact triggering the next one. The 
levels of pro-insulin were very high (up to 9 times the upper 
laboratory reference range). Pro-insulin has weak insulin-like 
biological activity of its own right, but a much longer half-life 
than insulin. It might therefore have contributed to a reactive-
type of hypoglycaemic reactions. A diagnostic problem which 
was encountered was the fact that the octreotide scan is not 
always helpful, since the false negative rate could reach up to 
50% due to different types of somatostatin receptors present in 
this tumour type.7,8,9 
The duration of the prolonged fasting tests might not be the 
recommended one, however in this case it served its purpose 
since the difference between the 2 tests occurred after the 
glucose challenge; when the patient was on lithium there was 
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severe hypoglycaemia and while off lithium the patient did not 
suffer any adverse events. So the two scenarios were directly 
comparable. Furthermore, stopping lithium therapy has resulted 
in the total absence of further hypoglycaemic episodes to date, 
virtually ruling out insulinomas since no definite treatment for 
these tumours was undertaken. Furthermore the patient has not 
developed other conditions e.g. diabetes mellitus.
It is clear that further studies need to be carried out in order 
to investigate the role of lithium in causing hypoglycaemia. 
However any patient on lithium suffering from recurrent 
episodes of hypoglycaemia may need a review of psychiatric 
treatment. 
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The Department of Obstetrics and Gynaecology within 
the Faculty of Medicine and Surgery has been the recipient 
of a simulation model aimed at assisting the development of 
clinical skills by medical students. The Zoe® Gynaecologic 
Simulator was kindly donated by Mr. Simon Delicata who is 
the local representative of the international-based company 
Bayer-Schering Pharma. The model consists of a full-sized 
Donation of a clinical-skills simulation model 
by Bayer-Schering Pharma
adult female lower torso designed as a training tool developed 
to assist health professionals to teach the processes and skills 
required to perform certain gynaecological procedures. 
Bayer Schering Pharma AG is an international healthcare 
company that is committed to sustainable development 
in various fields of healthcare including gynaecology. The 
present donation is a clear example of the commitment being 
shown by the company of the positive inter-relationship 
between industry and academia. The company has strongly 
supported the Department of Obstetrics and Gynaecology 
throughout the last years. It has set up the annual Bayer-
Schering Pharma Prize in Obstetrics & Gynaecology that is 
awarded to the student who obtains the highest aggregate 
mark in the speciality during the final examinations of the 
Medicine and Surgery course. In addition, the company has 
sponsored publications on the history of midwifery education 
and on the history of gynaecology in Malta prepared by the 
Department. The present gift is a welcome addition to the 
educational tools armamentarium of the Faculty since it helps 
augment the clinical skills simulation laboratories being set 
up by the Faculty.
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Abstract
Aim: Patients undergoing bypass graft placement in the 
lower limb are often entered into a graft surveillance programme 
using duplex scanning. The aim of this programme is to identify 
stenoses in vein grafts before they become symptomatic and 
treat these by angioplasty or surgery, thus prolonging the 
patency of the graft. This paper aims at reporting on the progress 
and viability of this programme at Mater Dei Hospital, Malta.
Method: Infrainguinal bypass grafts carried out between 
July 2007 and May 2009 were enrolled. Scanning starts during 
the patient’s in-hospital stay at one week post-operation.  It is 
then scheduled at 6 weeks, 3 months, 6 months, 12 months, 18 
months, 24 months, and yearly afterwards. When a significant 
stenosis is encountered, the patient is referred for angioplasty. 
Surgery would be considered in cases when angioplasty is not 
an option.
Results: During this period 56 patients were recruited. At 
one week post-op the patency rate was 100%.  At 6 months 
the primary unassisted patency was 77.5% while the primary 
assisted patency was 87.5%. At 12 months the primary 
unassisted patency was 50% while the primary assisted patency 
was 77%.  Secondary patency rates at 6 and 12 months were 95% 
and 82% respectively.
Conclusion: The graft surveillance programme ensures that 
any problem detected in the post-operative period is dealt with 
as soon as possible. The study shows that this programme is 
being effective in that assisted rates (i.e. after angioplasty or 
surgery) are better than unassisted rates.
Introduction
For patients with severe peripheral vascular disease, 
especially those with long occlusions of the superficial femoral 
and popliteal arteries, infrainguinal vascular bypass surgery 
may be the only option for revascularization of the limb.1-4 
There are three main types of infrainguinal bypass surgery – 
femoro to above knee popliteal bypass, femoro to below knee 
popliteal bypass and femoro to distal bypass. The latter can be 
femoro to anterior tibial, femoro to posterior tibial or femoro to 
peroneal bypass. Once patients have been scheduled for a bypass 
procedure they are assessed medically to check whether they 
are fit for the operation and they are scanned by the vascular 
surgeon in charge to look for any suitable vein graft which can 
be used as a new conduit. Vein grafts are preferred over PTFE 
grafts as they have longer patency than the latter.  Patients who 
undergo such operations are not simply discharged once they 
have recovered from their operation, but are followed up on a 
regular basis to check the progress of their graft and therefore 
of their clinical condition.  
This is in accordance with the recommendations of The 
Trans-Atlantic Inter-Society Consensus on the Management of 
Peripheral Arterial Disease (TASC), which states that patients 
“who undergo bypass graft placement in the lower extremity 
for the treatment of claudication or limb-threatening ischaemia 
should be entered into a clinical surveillance program.“ 1 This 
consists of asking the patients how they are doing in regards to 
their previous symptoms and whether any new symptoms have 
developed since the operation.  Vascular examination of the 
lower limb should take place as well with palpation of inflow, 
graft and outflow vessel pulses.  Resting and post-exercise Ankle 
brachial pressure indices (ABPI) should be measured as well.
Although strictly not a TASC recommendation, as ongoing 
trials are still needed to determine its efficacy, many surgeons 
also enter their patients into a graft surveillance programme 
whereby the graft is scanned by duplex ultrasound at regular 
intervals. The aim of this scanning is to check that the graft is 
working and to detect and treat any stenosis in the graft. This 
article reports on the setting up of such a graft surveillance 
programme in Malta.
Methods
Once a patient undergoes a vascular bypass operation he or 
she spends a day in an ITU/HDU setting and is then transferred 
to a normal surgical ward. The patient is seen daily to monitor 
his or her progress and at one week post-op the first graft 
scanning takes place.  The scanning needs to answer two main 
questions:
• Is the graft working? 
• Is there any stenosis?
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Duplex ultrasound Doppler is used to answer these 
questions, by means of waveform analysis and peak systolic 
velocities measurement. Colour Doppler is used to detect blood 
flow (Figures 1 and 2). 5-6
In terms of waveform analysis, triphasic waveforms 
represent better blood flow than biphasic which are in turn 
better than monophasic waveforms.
Blood flow is assessed in the artery proximal to the graft, the 
graft itself and the outflow artery. An increase in Peak Systolic 
Velocity of more than 3 times along the vessel is considered 
significant and is suggestive of a stenosis (Figure 3).5-6   Peak 
systolic velocities of less than 20cm/sec indicate that the 
flow through that segment of graft is poor and may require 
intervention.7  
Stenosis may occur at any site along the graft including the 
proximal and distal anastomosis. 
If during this process any stenosis is identified the patient can 
then be sent for angioplasty of the stenosis. This ideally should 
happen before such a stenosis becomes clinically significant. 
Sometimes graft scanning will reveal long occlusions which are 
not amenable to angioplasties.  In such cases, if possible, the 
patient will be offered redo bypass surgery.
Scanning takes place at one week post-op, then continues at 
6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months 
and yearly afterwards.  Only patients who underwent bypasses 
using vein grafts are scanned. PTFE grafts are not routinely 
scanned as they cannot be angioplastied should the need arise.  
This report covers graft scanning done for those infrainguinal 
bypasses carried out between August 2007 and May 2009 at St 
Luke’s Hospital and Mater Dei Hospital by the firm of one of 
the authors (KC).
Records for primary unassisted patency, primary assisted 
patency, and secondary patency were kept. Primary unassisted 
patency refers to patency of the graft without any intervention. 
Primary assisted patency refers to patency of the graft with the 
help of angioplasties when stenosis occurs, whilst secondary 
patency refers to those cases where the graft is occluded and needs 
surgical intervention (redo bypass) to revascularise the limb.  
Results
Our study period was over 22 months (from August 2007 
to May 2009). During this period sixty infrainguinal vascular 
bypasses were done.  These patients entered the study at 
different times; therefore not all of them had the same number 
of scans post-op. Those patients who were operated near the end 
of the study period, had only a few number of scans. 
Post-operatively at 1 week all the grafts were patent. Out of 
the 60 patients, 56 made it to the first scan at one week post op 
and these were all patent. 
At 6 weeks, 49 patients were scanned and 46 grafts were patent 
(94%). One of the other patients had successful redo vascular 
bypass surgery bringing the secondary patency rate to 96%. 
At 3 months, 44 patients had their grafts scanned and 40 
patients had patent grafts (90%). Another patient needed redo 
surgery and this brings the secondary patency rate up to 95%. 
At 6 months 31 out of the 40 patients scanned had their 
grafts patent (77.5%). Four other patients had successful 
angioplasty bringing the primary assisted patency to 87.5%. 
Secondary patency was 95% (38 out of 40 patients).
At 12 months 22 patients were scanned.  At this point 
primary unassisted patency was 50%, i.e. only 11 patients had 
their graft patent.  Primary assisted patency was much better at 
77%, with another 6 patients having angioplasties. Secondary 
patency was slightly better at 82% (18 patients out of 22).  
At 18 months only nine patients were scanned.  Four of these 
grafts were patent – 44% primary unassisted patency, while 
another patient had an angioplasty, thus putting the primary 
assisted patency at 56%. Another patient had redo-surgery with 
the secondary patency rate thus being 67%.
The above information is shown in Table 1 and in the Kaplan-
Meier curves (Figure 4) for the various patencies described 
above.  The primary end-point is sonographically detected 
graft stenosis.
Discussion
As we can see from the figures in the table below, primary 
assisted patency and secondary patency were significantly better 
Figure 1: Good blood flow on Colour Doppler of a 
Saphenous Vein graft and biphasic waves on duplex 
ultrasound
Figure 2: Distal anastomosis of an in-situ bypass graft. The 
size of the graft (arrow) matches the diameter of the tibial 
artery (arrowhead)
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Time post-op
Number of 
patients
Primary 
Unassisted 
Patency
Primary Assisted 
Patency
Secondary
Patency
One week 56 56 (100%)
6 weeks 49 46 (94%) 46 (94%) 47 (96%)
3 months 44 40 (91%) 40 (91%) 42 (95%)
6 months 40 31 (77.5%) 35 (87.5%) 38 (95%)
12 months 22 11 (50%) 17 (77%) 18 (82%)
18 months 9 4 (44%) 5 (56%) 6 (67%)
Table 1: Primary unassisted patency, primary assisted patency and secondary patency for infrainguinal bypass grafts 
at different post-operative duplex scanning
than primary unassisted patency from the sixth month onwards. 
This indicates that the graft surveillance programme, which aims 
at treating significant stenoses or occlusions as soon as possible 
by sending them to angioplasty or surgery if necessary, is being 
efficient at detecting those patients who need further treatment. 
Were it not for the surveillance programme these patient might 
present at a later stage where treatment would be more complex, 
if at all possible. This is in keeping with several other studies 
which also mentioned the importance of graft surveillance by 
duplex ultrasound. 8-10 
Conclusion 
This study shows that a graft surveillance programme makes 
a lot of sense in the setting of infrainguinal bypass surgery and 
we look forward to official recommendations by TASC on this 
matter.
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Figure 3: Peak systolic velocities are elevated (295 cm/
sec) at the point of abnormal color Doppler signals. This 
indicates a focal stenosis of 50 to 75% in the native artery 
distal to the graft.
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Figure 4: Kaplan-Meier Curves for primary unassisted, 
primary assisted, and secondary patency rates. Figures 
below “time after operation” denote the number of 
patients at that stage
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Historical Perspective
The nurse of the Mediterranean
Saviour Pisani
During the First World War Malta did not take an active part 
in the fighting.  Britain was joined in an ‘entente’ a friendship 
agreement with France since 1904 and later with Russia in 
1907.  On the other hand Germany was allied to the Austrian-
Hungerian Empire, hence when the Great War started in July 
1914 there were France, Britain and Russia on one side and 
Germany and Austria-Hungary on the other.  The British fleet 
“ruled the waves”, hence with France and Britain as allies, to 
be joined later by Italy, the Mediterranean was more or less an 
allied lake, with Malta in the centre.
During the nineteenth century the Ottoman Empire was 
falling apart, and one of the big problems that faced the foreign 
office of Britain in the nineteenth century was the Ottoman 
Empire known as the sick man of Europe.    Russia was looking 
at it from the part of the chief inhibitor of its demise, while 
Britain was taking the role of a doctor.  Russia is a vast country, 
stretching from the Baltic to the Pacific and from the Arctic to the 
Black Sea.  Its biggest problem was that it could not use its ports 
throughout the whole year.  Its arctic port, the Archangel, was 
blocked by ice; its Baltic ports had a similar problem in winter. 
Furthermore the Baltic Sea was dominated by the German navy 
in XXXII.  The latter was secondary to that of Britain. Russia’s 
far eastern ports – Vladivostostock – was also frozen and far too 
distant.  The Black Sea ports were closed by the Ottoman Empire 
during hostilities.  The Russian ships had to pass through the 
Dardanelles to reach the Mediterranean and if the Dardanelles 
were under a hostile power no merchant ship could pass – i.e. 
the Russian navy was bottled up in the Black Sea.
The British were always suspicious of the Russian intentions 
towards the Ottoman Empire, and the Crimean War of 1854 
was fought by Britain, France and the Ottoman Empire against 
Russia to destroy its main base of Sevastapol and its fleet.  By 
the treaty of San Stefano and the convention of Berlin blocked by 
Bismarck, the small Balkan states of Bulgaria, Serbia, Rumania 
and Montenegro appeared and these showed that they were very 
jealous of their independence and were far more efficient than 
the decadent Ottoman Empire to thwart Russian ambitions 
to enter the Mediterranean Sea. Still the Balkans was not so 
stable and in 1911-1912 the Balkan Wars erupted.  In 1914 
after the Archduke Ferdinand was assassinated in Sarajevo, 
Austria-Hungary declared war on Serbia and the First World 
War started.  The Ottoman Empire had a friendly relationship 
with Germany, its military was trained by Prussian officers and 
when the battle cruisers – Goeben and Breslan – were caught in 
the Mediterranean in July 1914 and sailed on to Constantinople 
where they were given as a present to the Sultan, the Ottoman 
Empire found itself on the German side together, incidentally 
with Bulgaria which felt short-changed by Serbia.
The First World War started in high spirits by both sides. 
However, it soon degenerated in trench warfare.  The British 
old professional army, known as the old contemptible was soon 
decimated and new regiments came from Britain and its empire 
to replace the heavy losses.  The French also lost many soldiers 
when they moved on Alsace and Lorraine, lost in 1870.  The 
Russians lost thousands and thousands of soldiers in the battle 
of Tannenberg.  Their equipment was found most wanting and 
it was clear to all military chiefs that Russia could not sustain 
a war of attrition.  The soldiers went into battle without rifles, 
they had to pick rifles from dead or wounded colleagues as they 
advanced along the front.  The Russian army needed munitions, 
heavy guns, transport, rifles and all that a modern war entails. 
The French knew that if the Russian front were to collapse – as 
it did later in the war, the full fury of the German army would be 
let loose on them.  The only way available to supply them was by 
sea.  The Baltic Sea was dominated by the German fleet, while 
the Archangel was hardly practical.  Hence Winston Churchill, 
who was lord of the Admirality at that time, thought of supplying 
the Russian army from its Black Sea ports.  To do this he had 
to open the Dardanelles to allied shipping, which really meant 
he had to knock the Ottoman empire out of the war.  This he 
deemed a not so difficult task - after all the Ottoman Empire 
had been falling apart for more than a century, and it was kept 
in one piece thanks to the efforts of the British Government, the 
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chief interventionist being Disraeli.
Possibilities were very good. With Constantinople in British 
and French hands, the Russian army could be supplied. The Czar 
government secure from its internal enemies - the  Bolshevists – 
could initiate a new Russian offensive in the East, thus relieving 
the Western Front from pressure.
Churchill thought that the Dardanelles could be forced by 
the navy alone. In conjunction with the French, the British sent 
the pre-dreadnaughts.  This led to a major disaster, the Turkish 
waters were infested with mines and the approaches with heavy 
fortified forts.  The allies lost a number of battleships through 
enemy activity and German submarines were reputed to be in 
the area.  Hence it was thought that the Gallipoli Peninsula 
should be cleared of the hostile troops by landing troops on it 
– the Anzacs, Austrialian and New Zeland troops who were in 
Egypt at that time.  However, the element of surprise had been 
lost and when the troops finally landed they found the Turkish 
troops ready for them.  No real progress was done and after a few 
months, in which thousands of Allied troops were either killed 
or wounded, they were evacuated from the Gallipoli beaches, 
Winston Churchill resigned and eventually the Czar regime 
collapsed. Luckily the United States came into war on the side 
of the allies and the Western front was saved.
Malta was warned to get itself prepared to receive the 
wounded of the Gallipoli campaign.  The Governor at that time 
was Lord Melhuen who was a very good organiser.  Plans were 
immediately started to turn Malta into a giant hospital.  At that 
time there were four hospitals in Malta, the Central Hospital for 
civilians, the Blue Sisters’ hospital for merchant seamen, Bighi 
hospital for the navy and Mtarfa Hospital for the army.  Their 
total capacity was about three hundred beds, if all the rooms 
and available space were utilized there would be five hundred 
beds – far short of what was necessary. The Holy Infirmary at 
Valletta was roped into service. Some new schools were turned 
into hospitals and barracks which had been vacated by the troops 
turned into hospitals. Originally Allied command in Egypt asked 
for 3000 beds.  However, with mounting injuries it was soon 
found that that extimate was not nearly enough and more bed 
space was created.  A hospital is totally useless without adequate 
staff, doctors, nurses, attendants, labourers, technicians, cooks, 
laundry people, etc., etc.
The soldiers invaded the Gallipoli Peninsula on the 25th April 
1915. Many soldiers were wounded or killed. Up to the end of 
May 1915, 38,000 soldiers were either killed or wounded. These 
figures will make us understand the extent of the problem facing 
the authorities over here. The first wounded reached Malta on 
the 4th May 1915. They were carried on hospital ships, painted 
white with a big red cross painted on their sides. When the 
people realized that the wounded of Gallipoli were entering the 
bastions, the  mood was very sombre. The harbour had the aspect 
of a sick ward in a general hospital, silence all around.
One thousand two hundred solders, wounded from the front 
were brought on that day. Barges went against the hospital ships 
and the injured soldiers were brought down very gently by the 
cranes on stretchers and from the barges onto the shore. From 
the quay they were taken to the Holy Infirmary at Valletta where 
they were examined by top British and Maltese doctors, from 
there they were sent to other centres according to their injuries. 
A Maltese doctor appointed by the Governor himself for such 
duties was Dr Robert Randon who was placed in charge of Fort 
Tigne, now turned into a hospital of about 1,000 beds.
The processes of wounded soldiers on stretchers drawn 
by mules and horses passed through Kingsway, now Republic 
street, in Valletta on its way to the Holy Infirmary.  It was 
described as that of Good Friday, silence reigned and people 
on each side on the pavements welcomed the soldiers with 
cigarettes, sweets, flowers and chocolate.  The wounded soldiers 
most of them very young showed their appreciation by waving 
to the people and from that day the close bond between Malta 
and Australia was born.  Indeed a lot of these soldiers died in 
Malta and they were buried at Braxia Cemetery at Pietà near 
where the football club now stands.
May I be permitted here to read Rupert Brooke poem The 
Soldier written in that period of time.
If I should die, think only this of me
That there in a corner of a foreign field
That is forever England.  There shall be
In that rich earth a richer dust concealed.
A dust whom England bore, shaped, made aware
Gave, once, her flowers to love, her ways to name,
A body of England’s , breathing English air,
Washed by the XX, blast by suns of home.
Perhaps if we were to substitute Australia for England here, 
we can better understand the atmosphere, the sorrow and 
anguish that reigned in Malta that summer of 1915.
Up till the end of May, 4000 wounded had arrived and 
they were bring treated in 8 hospitals.  By September, 10,000 
wounded had arrived.  By March 1916, there were 20,000 
hospital beds, in all 80,000 soldiers were treated in Malta.  A 
percentage of them found their grave in Malta.  Military funerals 
were the order of the day, sometimes with eight or more dead 
soldiers buried on the same day. Since these funerals were 
having a depressing effect on the general population, it was 
decided to conduct them from outside the limits of Floriana, 
from Portes des Bombes to Braxia cemetery.
The Gardens of Argotti, the Mall, and the streets of 
Valletta were all full of wounded soldiers.  Some of them had 
an amputated arm pushing at colleague in a wheelchair with 
amputated legs.  Some had bandaged heads, others were 
blind.  However, they were cheerful and made friends with 
the Maltese people who opened the doors of their homes and 
hearts to them.  Ladies organised tea parties and concerts for 
them.  They started to sponsor children by giving them cards 
found in cigarette boxes.  In general the soldiers who survived 
the Gallipoli experience were quite happy for things could have 
been far worse for them.  In all they were treated in 27 military 
hospitals, one of them being the newly built school of Sliema. 
Archbishop Caruana was asked to tell the parish priests not to 
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rash, urticaria, weakness, muscle spasm, interstitial nephritis, renal dysfunction, fever. Laboratory values: electrolyte imbalance, including hypokalaemia and hyponatraemia, hyperuricaemia, glycosuria, hyperglycaemia, increases in cholesterol and triglycerides. Legal Category: POM. Pack sizes: 7, 
28 film-coated tablets. Marketing Authorisation Holder: Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex, RH12 5AB, United Kingdom. Marketing Authorisation Numbers: Rasilez HCT 300/12.5 mg - EU/1/08/491/041-060. Rasilez HCT 300/25 mg - EU/1/08/491/061/080. 
Please refer to Summary of Product Characteristics (SmPC) before prescribing. Full prescribing information is available on request from Novartis Pharma, P.O. Box 124, Valletta, VLT 1000, Malta. Tel +356 22983217. (2010-MT- RASHCT June 2010).
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ring the bells to let the patients rest.  The Archbishop obliged 
and the bells stopped ringing.  
Ghajn Tuffieha was tunred into a giant camp for convalescent 
soldiers. In all there were 4,000 beds under tents.  Three 
hundred civilian and military doctors were employed.  Some 
top British surgeons came to Malta, like Balance and Garrod, 
and 1000 British nurses came from the UK.
Gradually things started to calm down.  It was obvious that 
the Allies were making no headway in Gallipoli and they were 
pushed back.  However, on the 25th December 1915 the British 
and the French landed in Salonika to help the Serbians.  The 
First World War started from Serbia. In the Balkan wars of 1911 
and 1912, Bulgaria was offered Macedonia but its share went 
to Greece and Serbia.  Hence Serbia was attacked by Bulgaria, 
and the British and French went to help.  This time the Maltese 
makeshift hospitals were filled with malaria and typhoid.  It is 
interesting to note that the first cardiac operation was done in 
Malta on a soldier who had been shot by a Bulgarian sniper.
As the Gallipoli and Salonika campaigns subsided so did the 
Maltese hospitals empty, to fill again by the Spanish Influenza 
victims.  Employment during the war and when the war finished 
there was massive unemployment in Malta.  A lot of ships had 
been sunk, food was scarce and hard to get, there was massive 
inflation and the safety valve of emigration non-existent since 
Australia had problems of its own.  With political aspirations 
on the increase, the unemployed workers looked at the political 
leaders like Sir Filippo Sciberras and the next scene was the 
Sette Gungio rites of 1919.
When the First World War was nearly over the so-called 
Spanish Flu appeared.  The pandemic killed more people than 
the war itself, although one can attribute it to the war itself. 
When there is mass movement of troops and civilians with the 
most basic requisites of hygiene ignored and non-existent, one 
can expect epidemics.  In WW1 Spain was neutral and the first 
reported cases came from Spain since the censorship of the media 
was free.  It appeared in the US where young people were being 
called for service in Europe by Widrow Witson, thousands died 
in their training camps.  It infected the allied army in Northern 
France where a depot was located and then spread to the German 
army.  In all there were three waves of this pandemic and it was 
characterized by fever, breathing problems, haemoptysis and 
cyanosis.  Hence our hospitals started to fill again on the 4th 
October 1918. The Government issued regulations to prevent 
the spread of the disease – avoiding overcrowding and general 
cleanliness.  Between the 1st September 1918 and 1st March 1919 
there were 651 deaths.  March was the high point of the third 
wave.  The Influenza continued onto 1920. In February and 
March 656 cases were reported with a mortality of over 30%. 
The total mortality of the 1918 – 1919 pandemic in Malta was 3 
per 1000 of the population.
On the 10th December 1917 His Excellency the Governer 
declared at the beginning of the session of the Council of 
Government. “I also desire to record my grateful recognition of 
the sympathetic hospitality which the people of Malta and Gozo 
have extend to the sick and wounded that have been brought 
during the war, of the support that they have given to the British 
Red Cross and the Order of St John of Jerusalem and the other 
charitable institutions that have been formed.”  This was not 
the first time that Malta took the role of a Nurse in Wartime 
and it is said that Malta had added a bright chapter to human 
history and the severance to its hospitals ever be named; for 
their sacrifice has once more been enthroned, and unselfishness, 
garbed in nurses’ cape or surgoens’ uniform, proclaimed the 
triumph of love.
Malta Medical Journal    Volume 22   Issue 03   2010 31
Historical Perspective
Professional medical journal publications 
in Malta
Abstract
After the establishment of freedom of the press in 1839, 
the Maltese medical community initiated the publication of 
a medical journal in their efforts to maintain professional 
standards through continuing medical education. The first 
initiatives unfortunately were often relatively short-lived due 
to a number of factors. These initiatives were often undertaken 
by individuals and were often dependant on paid subscription 
for their maintenance. Longer lasting publications required a 
change in management policies. The second half of the twentieth 
century saw the first long-lasting initiative being undertaken by 
the medical student association; this journal’s financial support 
being dependant on income from advertisements. Twenty 
years later, the Faculty of Medicine and Surgery initiated a 
professional journal. These two journals have since changed 
their name and editorial policies but are still extant in the current 
publications Murmur and the Malta Medical Journal.
The governments occupying the Maltese Islands had 
always been on their guard against any form of sedition that 
could ferment dissent against their governance. This policy 
required a strict control of locally published material of any 
form. The French occupation and the subsequent insurrection 
had however deeply instilled the concept of freedom, including 
freedom of speech. In the early decades of the 19th century, the 
Maltese political movement Comitato Generale Maltese under 
Charles Savona Ventura
the leadership of George Mitrovich and Camillo Sciberras 
started pressurising the British Government for a more liberal 
governance constitution. This political pressure saw the setting 
up of the 1836 Austin-Lewis Commission that, among other 
things, was favourable to the introduction of freedom of the 
press provided that the public interest and loyalty to the British 
Crown was preserved. By 1838, even before the formal legal 
withdrawal of press censorship through Ordinance IV published 
22nd March 1839, two newspapers - Lo Spettatore Imparziale 
and Il Portafoglio Maltese - initiated publication. The eventual 
publication of the ordinance saw a sudden proliferation of 
newspapers such as The Harlequin, and Il Mediterraneo - 
Gazzetta di Malta.1 
The withdrawal of press censorship was quickly availed 
of by the medical community in Malta. In the last quarter of 
1838, before the formal withdrawal of press censorship, Dr. 
C.G. Schinas issued L’Ape Melitensis - Giornale di Medicina 
with the aim of compiling a journal that appealed to both new 
graduates and the more experienced professional. The journal 
served to review contemporary medical literature with material 
being written in the Italian language by the editor himself. 
L’Ape Melitensis ran for only four issues through September 
to December 1838, the whole volume amounting to 288 pages. 
Besides the reviews, the journal also include seven original 
articles that dealt with the 1837 cholera epidemic, Werlhoff’s 
purpura, smallpox vaccination, the pharmacology of Segala 
Cornuta, the use of calomel in intestinal disorders, animal 
magnetism, phrenology and a description of an improved 
urinary catheter designed by Dr. Giuseppe Stilon.2
The initiative for establishing a medical journal was again 
taken up on the 1st January 1841 by Dr. C. G. Schinas together 
with the assistance of the doctors on the staff of the Civil, 
Ta’ Sawra and Santo Spirito Hospitals. This editorial board 
undertook the publication of a new journal entitled Il Filocano 
- Giornale Medico Scientifico e di Educazione circulated to 
subscribers against payment [annual subscription: 2s0d]. 
Initially published monthly, it soon increased its publication 
frequency to fortnightly. This journal had a wider remit than the 
previous medical publication, and served as a medium for local 
and foreign practitioners to publish their views and observations 
including case descriptions. Its articles included discussions on 
smallpox and its prophylaxis, and the management of conditions 
such as tetanus, puerperal sepsis, and mental disease. Il Filocano 
was first issued in January 1841 and was eventually published 
fortnightly. It ceased publication in December 1842 after 
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FOSAVANCE™ (alendronate/colecalciferol) and FOSAMAX™
(alendronate)  are trademarks of Merck Sharp & Dohme Corp.,
a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, U.S.A.
FOSAVANCE 5600 retail price (Pack of 4)     € 37,55
FOSAVANCE™  is indicated for treatment of postmenopausal osteoporosis in 
patients who are not receiving vitamin D supplementation and are at risk of vitamin D 
insuffi  ciency.  FOSAVANCE reduces the risk of vertebral and hip fractures.1
FOSAMAX™ and FOSAVANCE are contraindicated in patients with esophageal 
abnormalities which delay esophageal emptying (eg, stricture or achalasia) and 
in patients unable to stand or sit upright for at least 30 minutes. FOSAMAX and 
FOSAVANCE are contraindicated in patients with hypocalcemia (see WARNINGS 
AND PRECAUTIONS) and in patients with hypersensitivity to any component of these 
products. Hypersensitivity reactions including urticaria and angioedema have been 
reported. FOSAMAX and FOSAVANCE, like other bisphosphonates, may cause local 
irritation of the upper gastrointestinal mucosa.1
In postmarketing experience, severe and occasionally incapacitating bone, joint, 
and/or muscle pain has been reported in patients taking bisphosphonates that 
are approved for the prevention and treatment of osteoporosis. The time to onset 
of symptoms varied from one day to several months after starting the drug. 
Discontinue use if severe symptoms develop. Most patients had relief of 
symptoms after stopping treatment.1
Osteonecrosis of the jaw, generally associated with tooth extraction and/or 
local infection, often with delayed healing, has been reported in patients 
taking bisphosphonates.1
NOF = National Osteoporosis Foundation.
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 The Only Osteoporosis Therapy 
That Provides
•  Demonstrated Fracture Prevention 
at the Hip and Spine Plus 5,600 IU 
of Vitamin D
•  In a Single, Once-Weekly Tablet
 Actual size
1. NAME OF THE MEDICINAL PRODUCT
FOSAVANCE™ 70 mg/5600 IU tablets
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 70 mg alendronic acid as alendronate sodium
trihydrate and 140 micrograms (5600 IU) colecalciferol (vitamin D3).
Excipients:
Each tablet contains 63 mg lactose anhydrous and 16 mg sucrose.
For a full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Tablet.
Modified rectangle-shaped, white to off-white tablets, marked with an
outline of a bone image on one side, and ‘270’ on the other.
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Treatment of postmenopausal osteoporosis in patients who are not receiving
vitamin D supplementation and are at risk of vitamin D insufficiency. 
FOSAVANCE reduces the risk of vertebral and hip fractures.
4.2 Posology and method of administration
The recommended dosage is one FOSAVANCE tablet once weekly.
Due to the nature of the disease process in osteoporosis, FOSAVANCE is
intended for long-term use.
To permit adequate absorption of alendronate:
FOSAVANCE must be taken with water only (not mineral water) at least
30 minutes before the first food, beverage, or medicinal product (including
antacids, calcium supplements and vitamins) of the day. Other beverages
(including mineral water), food and some medicinal products are likely to
reduce the absorption of alendronate (see section 4.5).
The following instructions should be followed exactly in order to minimize
the risk of oesophageal irritation and related adverse reactions (see
section 4.4):
FOSAVANCE should only be swallowed after getting up for the day with a full
glass of water (not less than 200 ml or 7 fl.oz.).
Patients should only swallow FOSAVANCE whole. Patients should not
crush or chew the tablet or allow the tablet to dissolve in their mouths
because of a potential for oropharyngeal ulceration.
Patients should not lie down until after their first food of the day which
should be at least 30 minutes after taking the tablet.
Patients should not lie down for at least 30 minutes after taking
FOSAVANCE.
FOSAVANCE should not be taken at bedtime or before arising for the day.
Patients should receive supplemental calcium if intake from diet is
inadequate (see section 4.4). The equivalence of intake of 5600 IU of
vitamin D3 weekly in FOSAVANCE to daily dosing of vitamin D 800 IU has
not been studied.
Use in the elderly:
In clinical studies there was no age-related difference in the efficacy or
safety profiles of alendronate. Therefore no dosage adjustment is necessary
for the elderly.
Use in renal impairment:
No dosage adjustment is necessary for patients with a glomerular filtration
rate (GFR) greater than 35 ml/min. FOSAVANCE is not recommended for
patients with renal impairment where GFR is less than 35 ml/min, due to
lack of experience.
Use in children and adolescents:
FOSAVANCE has not been studied in children and adolescents and therefore
should not be given to them.
4.3 Contraindications
Hypersensitivity to the active substances or to any of the excipients.
Abnormalities of the oesophagus and other factors which delay
oesophageal emptying such as stricture or achalasia.
Inability to stand or sit upright for at least 30 minutes.
Hypocalcaemia.
4.4 Special warnings and precautions for use
Alendronate 
Alendronate can cause local
irritation of the upper gastrointestinal mucosa. Because there is a potential
for worsening of the underlying disease, caution should be used when
alendronate is given to patients with active upper gastrointestinal problems,
such as dysphagia, oesophageal disease, gastritis, duodenitis, ulcers, or
with a recent history (within the previous year) of major gastrointestinal
disease such as peptic ulcer, or active gastrointestinal bleeding, or surgery
of the upper gastrointestinal tract other than pyloroplasty (see section 4.3).
In patients with known Barrett’s oesophagus, prescribers should consider
the benefits and potential risks of alendronate on an individual patient basis.
Oesophageal reactions (sometimes severe and requiring hospitalisation),
such as oesophagitis, oesophageal ulcers and oesophageal erosions, rarely
followed by oesophageal stricture, have been reported in patients receiving
alendronate. Physicians should therefore be alert to any signs or symptoms
signalling a possible oesophageal reaction and patients should be instructed
to discontinue alendronate and seek medical attention if they develop
symptoms of oesophageal irritation such as dysphagia, pain on swallowing
or retrosternal pain or new or worsening heartburn (see section 4.8).
The risk of severe oesophageal adverse reactions appears to be greater
in patients who fail to take alendronate properly and/or who continue to
take alendronate after developing symptoms suggestive of oesophageal
irritation. It is very important that the full dosing instructions are provided to,
and are understood by the patient (see section 4.2). Patients should be
informed that failure to follow these instructions may increase their risk of
oesophageal problems.
While no increased risk was observed in extensive clinical trials with
alendronate, there have been rare (post-marketing) reports of gastric and
duodenal ulcers, some of which were severe and with complications (see
section 4.8).
Osteonecrosis of the jaw, generally associated with tooth extraction
and/or local infection (including osteomyelitis) has been reported in patients
with cancer who are receiving treatment regimens including primarily
intravenously administered bisphosphonates. Many of these patients were
also receiving chemotherapy and corticosteroids. Osteonecrosis of the jaw
has also been reported in patients with osteoporosis receiving oral
bisphosphonates. 
A dental examination with appropriate preventive dentistry should be
considered prior to treatment with bisphosphonates in patients with
concomitant risk factors (e.g. cancer, chemotherapy, radiotherapy,
corticosteroids, poor oral hygiene, periodontal disease). 
While on treatment, these patients should avoid invasive dental
procedures if possible. For patients who develop osteonecrosis of the jaw
while on bisphosphonate therapy, dental surgery may exacerbate the
condition. For patients requiring dental procedures, there are no data
available to suggest whether discontinuation of bisphosphonate treatment
reduces the risk of osteonecrosis of the jaw.
Clinical judgement of the treating physician should guide the
management plan of each patient based on individual benefit/risk
assessment.
Bone, joint, and/or muscle pain has been reported in patients taking
bisphosphonates. In post-marketing experience, these symptoms have
rarely been severe and/or incapacitating (see section 4.8). The time to onset
of symptoms varied from one day to several months after starting
treatment. Most patients had relief of symptoms after stopping treatment. A
subset had recurrence of symptoms when rechallenged with the same
medicinal product or another bisphosphonate.
Stress fractures (also known as insufficiency fractures) of the proximal
femoral shaft have been reported in patients treated long-term with
alendronic acid (time to onset in the majority of cases ranged from
18 months to 10 years). The fractures occurred after minimal or no trauma
and some patients experienced thigh pain, often associated with imaging
features of stress fractures, weeks to months before presenting with a
completed femoral fracture. Fractures were often bilateral; therefore the
contralateral femur should be examined in bisphosphonate-treated patients
who have sustained a femoral shaft fracture. Poor healing of these fractures
was also reported. Discontinuation of bisphosphonate therapy in patients
with stress fracture is advisable pending evaluation of the patient, based on
an individual benefit risk assessment. 
Patients should be instructed that if they miss a dose of FOSAVANCE
they should take one tablet on the morning after they remember. They
should not take two tablets on the same day but should return to taking one
tablet once a week, as originally scheduled on their chosen day.
FOSAVANCE is not recommended for patients with renal impairment
where GFR is less than 35 ml/min (see section 4.2).
Causes of osteoporosis other than oestrogen deficiency and ageing
should be considered.
Hypocalcaemia must be corrected before initiating therapy with
FOSAVANCE (see section 4.3). Other disorders affecting mineral metabolism
(such as vitamin D deficiency and hypoparathyroidism) should also be
effectively treated before starting FOSAVANCE. The content of vitamin D in
FOSAVANCE is not suitable for correction of vitamin D deficiency. In patients
with these conditions, serum calcium and symptoms of hypocalcaemia
should be monitored during therapy with FOSAVANCE.
Due to the positive effects of alendronate in increasing bone mineral,
decreases in serum calcium and phosphate may occur especially in patients
taking glucocorticoids in whom calcium absorption may be decreased.
These are usually small and asymptomatic. However, there have been rare
reports of symptomatic hypocalcaemia, which have occasionally been
severe and often occurred in patients with predisposing conditions (e.g.
hypoparathyroidism, vitamin D deficiency and calcium malabsorption) (see
section 4.8).
Colecalciferol
Vitamin D3 may increase the magnitude of hypercalcaemia and/or
hypercalciuria when administered to patients with disease associated with
unregulated overproduction of calcitriol (e.g. leukaemia, lymphoma,
sarcoidosis). Urine and serum calcium should be monitored in these
patients.
Patients with malabsorption may not adequately absorb vitamin D3.
Excipients
This medicinal product contains lactose and sucrose. Patients with rare
hereditary problems of fructose intolerance, galactose intolerance, the Lapp
lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase
insufficiency should not take this medicinal product.
4.5 Interaction with other medicinal products and other forms of
interaction
Alendronate 
If taken at the same time, it is likely that food and beverages (including
mineral water), calcium supplements, antacids, and some oral medicinal
products will interfere with absorption of alendronate. Therefore, patients
must wait at least 30 minutes after taking alendronate before taking any
other oral medicinal product (see sections 4.2 and 5.2).
No other clinically significant interactions with medicinal products are
anticipated. A number of patients in the clinical trials received oestrogen
(intravaginal, transdermal, or oral) while taking alendronate. No adverse
reactions attributable to their concomitant use were identified.
Since NSAID use is associated with gastrointestinal irritation, caution
should be used during concomitant use with alendronate.
Although specific interaction studies were not performed, in clinical
studies alendronate was used concomitantly with a wide range of
commonly prescribed medicinal products without evidence of interactions of
clinical relevance.
Colecalciferol
Olestra, mineral oils, orlistat, and bile acid sequestrants (e.g.
cholestyramine, colestipol) may impair the absorption of vitamin D.
Anticonvulsants, cimetidine and thiazides may increase the catabolism of
vitamin D. Additional vitamin D supplements may be considered on an
individual basis.
4.6 Pregnancy and lactation
FOSAVANCE is only intended for use in postmenopausal women and
therefore it should not be used during pregnancy or in breast-feeding
women.
There are no adequate data from the use of FOSAVANCE in pregnant
women. Animal studies with alendronate do not indicate direct harmful
effects with respect to pregnancy, embryonal/foetal development, or
postnatal development. Alendronate given during pregnancy in rats caused
dystocia related to hypocalcaemia (see section 5.3). Studies in animals have
shown hypercalcaemia and reproductive toxicity with high doses of
vitamin D (see section 5.3).
It is not known whether alendronate is excreted into human breast milk.
Colecalciferol and some of its active metabolites pass into breast milk. 
4.7 Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been
performed.
However, certain adverse reactions that have been reported with
FOSAVANCE may affect some patients’ ability to drive or operate machinery.
Individual responses to FOSAVANCE may vary (see section 4.8). 
4.8 Undesirable effects
The following adverse reactions have been reported during clinical studies
and/or post-marketing use with alendronate.
No additional adverse reactions have been identified for FOSAVANCE.
[Common (≥ 1/100, < 1/10), uncommon (≥ 1/1,000, < 1/100), rare
(≥ 1/10,000, < 1/1,000), very rare (< 1/10,000)]
Nervous system disorders: Common: headache  Eye disorders: Rare:
uveitis, scleritis, episcleritis Gastrointestinal disorders: Common:
abdominal pain, dyspepsia, constipation, diarrhoea, flatulence, oesophageal
ulcer*, dysphagia*, abdominal distension, acid regurgitation
Uncommon: nausea, vomiting, gastritis, oesophagitis*,oesophageal
erosions*, melena
Rare: oesophageal stricture*, oropharyngeal ulceration*, upper
gastrointestinal PUBs (perforation, ulcers, bleeding)(see section 4.4). *See
sections 4.2 and 4.4
Skin and subcutaneous tissue disorders: Uncommon: rash, pruritus,
erythema, rare: rash with photosensitivity 
Very rare: severe skin reactions including Stevens-Johnson syndrome and
toxic epidermal necrolysis
Musculoskeletal and connective tissue disorders: Common:
musculoskeletal (bone, muscle or joint) pain
Rare: severe musculoskeletal (bone, muscle or joint) pain (see section 4.4)
Metabolism and nutrition disorders: Rare: symptomatic hypocalcaemia,
often in association with predisposing conditions. (see section 4.4)
General disorders and administration site conditions: Rare: transient
symptoms as in an acute-phase response (myalgia, malaise and rarely,
fever), typically in association with initiation of treatment.
Immune system disorders: Rare: hypersensitivity reactions including
urticaria and angioedema
During post-marketing experience the following reactions have been
reported (frequency not known):
Nervous system disorders: dizziness, dysgeusia
Ear and labyrinth disorders: Vertigo
Skin and subcutaneous tissue disorders: Alopecia
Musculoskeletal, connective tissue and bone disorders: Osteonecrosis
of the jaw has been reported in patients treated by bisphosphonates. The
majority of the reports refer to cancer patients, but such cases have also
been reported in patients treated for osteoporosis. Osteonecrosis of the jaw
is generally associated with tooth extraction and / or local infection
(including osteomyelitis). Diagnosis of cancer, chemotherapy, radiotherapy,
corticosteroids and poor oral hygiene are also deemed as risk factors (see
section 4.4); joint swelling; stress fractures of the proximal femoral shaft
(see section 4.4)
General disorders and administration site conditions: asthenia,
peripheral oedema
Laboratory test findings
In clinical studies, asymptomatic, mild and transient decreases in serum
calcium and phosphate were observed in approximately 18 % and 10 %,
respectively, of patients taking alendronate 10 mg/day versus approximately
12 % and 3 % of those taking placebo. However, the incidences of
decreases in serum calcium to < 8.0 mg/dl (2.0 mmol/l) and serum
phosphate to £ 2.0 mg/dl (0.65 mmol/l) were similar in both treatment
groups.
4.9 Overdose
Alendronate 
Hypocalcaemia, hypophosphataemia and upper gastrointestinal adverse
reactions, such as upset stomach, heartburn, oesophagitis, gastritis, or
ulcer, may result from oral overdose.
No specific information is available on the treatment of overdose with
alendronate. In case of overdose with FOSAVANCE, milk or antacids should
be given to bind alendronate. Owing to the risk of oesophageal irritation,
vomiting should not be induced and the patient should remain fully upright.
Colecalciferol
Vitamin D toxicity has not been documented during chronic therapy in
generally healthy adults at a dose less than 10,000 IU/day. In a clinical study
of healthy adults a 4,000 IU daily dose of vitamin D3 for up to five months
was not associated with hypercalciuria or hypercalcaemia.
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Bisphosphonates, combinations, ATC code:
M05BB03. 
FOSAVANCE is a combination tablet containing the two active
substances alendronate sodium trihydrate and colecalciferol (vitamin D3).
Alendronate 
Alendronate sodium is a bisphosphonate that inhibits osteoclastic bone
resorption with no direct effect on bone formation. Preclinical studies have
shown preferential localisation of alendronate to sites of active resorption.
Activity of osteoclasts is inhibited, but recruitment or attachment of
osteoclasts is not affected. The bone formed during treatment with
alendronate is of normal quality.
Colecalciferol (vitamin D3)
Vitamin D3 is produced in the skin by conversion of 7-dehydrocholesterol to
vitamin D3 by ultraviolet light. In the absence of adequate sunlight
exposure, vitamin D3 is an essential dietary nutrient. Vitamin D3 is
converted to 25-hydroxyvitamin D3 in the liver, and stored until needed.
Conversion to the active calcium-mobilizing hormone
1,25-dihydroxyvitamin D3 (calcitriol) in the kidney is tightly regulated. The
principal action of 1,25 dihydroxyvitamin D3 is to increase intestinal
absorption of both calcium and phosphate as well as regulate serum
calcium, renal calcium and phosphate excretion, bone formation and bone
resorption.
Vitamin D3 is required for normal bone formation. Vitamin D
insufficiency develops when both sunlight exposure and dietary intake are
inadequate. Insufficiency is associated with negative calcium balance, bone
loss, and increased risk of skeletal fracture. In severe cases, deficiency
results in secondary hyperparathyroidism, hypophosphataemia, proximal
muscle weakness and osteomalacia, further increasing the risk of falls and
fractures in osteoporotic individuals. Supplemental vitamin D reduces these
risks and their consequences.
Osteoporosis is defined as bone mineral density (BMD) of the spine or
hip 2.5 standard deviations (SD) below the mean value of a normal young
population or as a previous fragility fracture, irrespective of BMD.
FOSAVANCE studies
The effect of the lower dose of FOSAVANCE (alendronate 70 mg/vitamin D3
2800 IU) on vitamin D status was demonstrated in a 15-week, multinational
study that enrolled 682 osteoporotic post-menopausal women (serum
25-hydroxyvitamin D at baseline: mean, 56 nmol/l [22.3 ng/ml]; range,
22.5-225 nmol/l [9-90 ng/ml]). Patients received the lower strength
(70 mg/2800 IU) of FOSAVANCE (n=350) or FOSAMAX (alendronate) 70 mg
(n=332) once a week; additional vitamin D supplements were prohibited.
After 15 weeks of treatment, the mean serum 25-hydroxyvitamin D levels
were significantly higher (26 %) in the FOSAVANCE (70 mg/2800 IU) group
(56 nmol/l [23 ng/ml]) than in the alendronate-only group (46 nmol/l
[18.2 ng/ml]). The percentage of patients with vitamin D insufficiency
(serum 25-hydroxyvitamin D < 37.5 nmol/l [< 15 ng/ml]) was significantly
reduced by 62.5 % with FOSAVANCE (70 mg/2800 IU) vs. alendronate-only
(12 % vs. 32 %, respectively), through week 15. The percentage of patients
with vitamin D deficiency (serum 25-hydroxyvitamin D <  22.5 nmol/l
[< 9 ng/ml]) was significantly reduced by 92 % with FOSAVANCE
(70 mg/2800 IU) vs. alendronate-only (1 % vs 13 %, respectively). In this
study, mean 25-vitamin D, 22.5 to 37.5 nmol/l [9 to < 15 ng/ml]) increased
from 30 nmol/l (12.1 ng/ml) to 40 nmol/l (15.9 ng/ml) at week 15 in the
FOSAVANCE (70 mg/2800 IU) group (n=75) and decreased from 30 nmol/l
(12.0 ng/ml) at baseline to 26 nmol/l (10.4 ng/ml) at week 15 in the
alendronate-only group (n=70). There were no differences in mean serum
calcium, phosphate, or 24-hour urine calcium between treatment groups.
The effect of the lower dose of FOSAVANCE (alendronate
70 mg/vitamin D3 2800 IU) plus an additional 2800 IU Vitamin D3 for a total
of 5600 IU (the amount of vitamin D3 in the higher dose of FOSAVANCE)
once weekly was demonstrated in a 24-week, extension study that enrolled
619 osteoporotic post-menopausal women.  Patients in the Vitamin D3 2800
group received FOSAVANCE (70 mg/2800 IU) (n=299) and patients in the
Vitamin D3 5600 group received FOSAVANCE (70 mg/2800 IU) plus an
additional 2800 IU vitamin D3 (n=309) once a week; additional vitamin D
supplements were allowed. After 24-weeks of treatment, the mean serum
25-hydroxyvitamin D levels were significantly higher in the Vitamin D3 5600
group (69 nmol/l [27.6 ng/ml]) than in the Vitamin D3 2800 group (64 nmol/l
[25.5 ng/ml]). The percentage of patients with vitamin D insufficiency was
5.4 % in the Vitamin D3 2800 group vs. 3.2 % in the Vitamin D3 5600 group
through the 24-week extension. The percentage of patients with vitamin D
deficiency was 0.3 % in the Vitamin D3 2800 group vs. zero in the
Vitamin D3 5600 group. There were no differences in mean serum calcium,
phosphate, or 24-hour urine calcium between treatment groups. The
percentage of patients with hypercalciuria at the end of the 24-week
extension was not statistically different between treatment groups.
Alendronate studies
The therapeutic equivalence of alendronate once weekly 70 mg (n=519)
and alendronate 10 mg daily (n=370) was demonstrated in a one-year
multicentre study of post-menopausal women with osteoporosis. The mean
increases from baseline in lumbar spine BMD at one year were 5.1 % (95 %
CI: 4.8, 5.4 %) in the 70 mg once-weekly group and 5.4 % (95 % CI: 5.0,
5.8 %) in the 10 mg daily group. The mean BMD increases were 2.3 % and
2.9 % at the femoral neck and 2.9 % and 3.1 % at the total hip in the
70 mg once weekly and 10 mg daily groups, respectively. The two treatment
groups were also similar with regard to BMD increases at other skeletal
sites.
The effects of alendronate on bone mass and fracture incidence in post-
menopausal women were examined in two initial efficacy studies of
identical design (n=994) as well as in the Fracture Intervention Trial (FIT:
n=6,459).
In the initial efficacy studies, the mean BMD increases with alendronate
10 mg/day relative to placebo at three years were 8.8 %, 5.9 % and 7.8 %
at the spine, femoral neck and trochanter, respectively. Total body BMD also
increased significantly. There was a 48 % reduction (alendronate 3.2 % vs
placebo 6.2 %) in the proportion of patients treated with alendronate
experiencing one or more vertebral fractures relative to those treated with
placebo. In the two-year extension of these studies BMD at the spine and
trochanter continued to increase and BMD at the femoral neck and total
body were maintained.
FIT consisted of two placebo-controlled studies using alendronate daily
(5 mg daily for two years and 10 mg daily for either one or two additional
years):
FIT 1: A three-year study of 2,027 patients who had at least one baseline
vertebral (compression) fracture. In this study alendronate daily reduced the
incidence of ³ 1 new vertebral fracture by 47 % (alendronate 7.9 % vs.
placebo 15.0 %). In addition, a statistically significant reduction was found
in the incidence of hip fractures (1.1 % vs. 2.2 %, a reduction of 51 %).
FIT 2: A four year study of 4,432 patients with low bone mass but
without a baseline vertebral fracture. In this study, a significant difference
was observed in the analysis of the subgroup of osteoporotic women (37 %
of the global population who correspond with the above definition of
osteoporosis) in the incidence of hip fractures (alendronate 1.0 % vs.
placebo 2.2 %, a reduction of 56 %) and in the incidence of ³ 1 vertebral
fracture (2.9 % vs. 5.8 %, a reduction of 50 %).
5.2. Pharmacokinetic properties
Alendronate 
Absorption
Relative to an intravenous reference dose, the oral mean bioavailability of
alendronate in women was 0.64 % for doses ranging from 5 to 70 mg when
administered after an overnight fast and two hours before a standardised
breakfast. Bioavailability was decreased similarly to an estimated 0.46 %
and 0.39 % when alendronate was administered one hour or half an hour
before a standardised breakfast. In osteoporosis studies, alendronate was
effective when administered at least 30 minutes before the first food or
beverage of the day.
The alendronate component in the FOSAVANCE (70 mg/5600 IU)
combination tablet is bioequivalent to the alendronate 70 mg tablet.
Bioavailability was negligible whether alendronate was administered
with, or up to two hours after, a standardised breakfast. Concomitant
administration of alendronate with coffee or orange juice reduced
bioavailability by approximately 60 %.
In healthy subjects, oral prednisone (20 mg three times daily for five
days) did not produce a clinically meaningful change in oral bioavailability of
alendronate (a mean increase ranging from 20 % to 44 %).
Distribution
Studies in rats show that alendronate transiently distributes to soft tissues
following 1 mg/kg intravenous administration but is then rapidly
redistributed to bone or excreted in the urine. The mean steady-state
volume of distribution, exclusive of bone, is at least 28 litres in humans.
Concentrations of alendronate in plasma following therapeutic oral doses
are too low for analytical detection (< 5 ng/ml). Protein binding in human
plasma is approximately 78 %.
Biotransformation
There is no evidence that alendronate is metabolised in animals or humans.
Elimination
Following a single intravenous dose of [14C]alendronate, approximately
50 % of the radioactivity was excreted in the urine within 72 hours and little
or no radioactivity was recovered in the faeces. Following a single 10 mg
intravenous dose, the renal clearance of alendronate was 71 ml/min, and
systemic clearance did not exceed 200 ml/min. Plasma concentrations fell
by more than 95 % within six hours following intravenous administration.
The terminal half-life in humans is estimated to exceed ten years, reflecting
release of alendronate from the skeleton. Alendronate is not excreted
through the acidic or basic transport systems of the kidney in rats, and thus
it is not anticipated to interfere with the excretion of other medicinal
products by those systems in humans.
Colecalciferol
Absorption
In healthy adult subjects (males and females), following administration of
FOSAVANCE 70 mg/5600 IU after an overnight fast and two hours before a
meal, the mean area under the serum-concentration-time curve
(AUC0-80 hrs) for vitamin D3 (unadjusted for endogenous vitamin D3 levels)
was 490.2 ng·hr/ml. The mean maximal serum concentration (Cmax) of
vitamin D3 was 12.2 ng/ml and the median time to maximal serum
concentration (Tmax) was 10.6 hours. The bioavailability of the 5600 IU
vitamin D3 in FOSAVANCE is similar to 5600 IU vitamin D3 administered
alone.
Distribution
Following absorption, vitamin D3 enters the blood as part of chylomicrons.
Vitamin D3 is rapidly distributed mostly to the liver where it undergoes
metabolism to 25-hydroxyvitamin D3, the major storage form. Lesser
amounts are distributed to adipose and muscle tissue and stored as
vitamin D3 at these sites for later release into the circulation. Circulating
vitamin D3 is bound to vitamin D-binding protein.
Biotransformation
Vitamin D3 is rapidly metabolized by hydroxylation in the liver to
25-hydroxyvitamin D3, and subsequently metabolized in the kidney to
1,25-dihydroxyvitamin D3, which represents the biologically active form.
Further hydroxylation occurs prior to elimination. A small percentage of
vitamin D3 undergoes glucuronidation prior to elimination.
Elimination
When radioactive vitamin D3 was administered to healthy subjects, the
mean urinary excretion of radioactivity after 48 hours was 2.4 %, and the
mean faecal excretion of radioactivity after 4 days was 4.9 %. In both cases,
the excreted radioactivity was almost exclusively as metabolites of the
parent. The mean half-life of vitamin D3 in the serum following an oral dose
of FOSAVANCE (70 mg/2800 IU) is approximately 24 hours.
Characteristics in patients 
Preclinical studies show that alendronate that is not deposited in bone is
rapidly excreted in the urine. No evidence of saturation of bone uptake was
found after chronic dosing with cumulative intravenous doses up to
35 mg/kg in animals. Although no clinical information is available, it is likely
that, as in animals, elimination of alendronate via the kidney will be reduced
in patients with impaired renal function. Therefore, somewhat greater
accumulation of alendronate in bone might be expected in patients with
impaired renal function (see section 4.2).
5.3 Preclinical safety data
Non-clinical studies with the combination of alendronate and colecalciferol
have not been conducted.
Alendronate 
Non-clinical data reveal no special hazard for humans based on
conventional studies of safety pharmacology, repeated dose toxicity,
genotoxicity and carcinogenic potential. Studies in rats have shown that
treatment with alendronate during pregnancy was associated with dystocia
in dams during parturition which was related to hypocalcaemia. In studies,
rats given high doses showed an increased incidence of incomplete foetal
ossification. The relevance to humans is unknown.
Colecalciferol
At doses far higher than the human therapeutic range, reproductive toxicity
has been observed in animal studies. 
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completing two volumes of a total of 256 pages.3 The subsequent 
three decades saw a dearth in medical journalism and the 
interim saw the publication of items of medical import in the 
local newspapers such as The Malta Times and Il Mediterraneo 
- Gazzetta di Malta.
The initiative to establish medical journalism was taken up 
again by Dr. Gavino Gulia who on the 25th July 1871 undertook 
to publish the medical journal Il Barth - Gazzetta di Medicina 
e Scienze Naturali. Published every forty days, this journal was 
available by subscription against payment [annual subscription: 
8s4d]. This new medical journal achieved a wide subscription 
so that within two years 90% of doctors practicing in Malta 
are reported to have subscribed to the journal. Unlike its 
predecessors, the journal published contributions in both the 
Italian and English language inviting articles from both Maltese 
and British practitioners. It discusses various aspects of medical 
practice on the islands addressing public health concerns, 
specific medical disorders and innovative management options. 
It also carried contributions related to botany and natural 
history reflecting the editor’s interests. It continued with 
regular publication until October 1877. During its six years of 
publication, Il Barth had in its pages striven to bring to the 
fore the major public health problems influencing the Maltese 
community besides serving as a medium to furnish continuing 
medical education for its professional readers.4
After 1877, medical journalism in Malta again went into 
hibernation for another thirteen years until the 15th March 1890 
when two doctors - Drs. Themistocles Zammit and Fabrizio 
Borg - undertook the publication of a new fortnightly journal in 
Italian entitled La Rivista Medica. Obtainable by subscription 
against payment [annual subscription: 6s0d], this journal was to 
continue publication until the 31st January 1892 having changed 
editorship to Drs. G. Busuttil and S. Cassar. During its near 
two-year publication, the journal had described a number of 
case studies and had outlined several local medical and surgical 
developments, which included the use of faradic and electrical 
stimulation in the management of perimetritis and facial 
palsy, and the performance of elective abdominal surgery and 
emergency Caesarean section.5 An attempt was subsequently 
made to revive La Rivista Medica by the Camera Medica in July 
1922 under the direction of Drs. A. Mizzi and P.P. Debono. This 
endeavour however was to result only in the publication of four 
issues, the last journal being published in June 1923.6
During the early decades of the twentieth century, the 
commercial pharmaceutical business owner Mr. Ciro Cherubino 
set out to edit and publish a medical journal Il Progresso 
Medico Chirurgico. Published during the period December 
1920 to October 1921, this journal included contributions 
dealing with local medical issues and also dealing with advances 
in therapeutics. It also carried advertisements for patent 
medicines reflecting the editor’s business interests.7 A similar 
later publication published by the pharmaceutical import 
company - A.M. Mangion Ltd. - was the quarterly newsletter 
Newsline, edited by Vincent Briffa, which made its appearance 
in September 1992 continuing publication until 1995. The scope 
of this journal was to primarily serve as a newsletter to the 
company and promote its products. It also carried occasional 
general articles related to specific pharmaceuticals and items 
of medical history.8 A similar commercial-biased journal that 
primarily serves as a newsletter and service promotion is the 
publication the St. Philip’s Hospital Newsletter first published 
in August 1996 [six issues: 1996-1997] and the currently running 
Dear doctor! – The Healthcare newsletter from Saint James 
Hospital first published in February 1999.9,10
In the latter part of the twentieth century, a move was 
made to sponsor medical journals through advertisements 
from commercial businesses, rather then rely solely on reader 
support. The first initiative of this type was taken by the Malta 
Branch of the British Medical Students Association [after 1956, 
the Malta Medical Students Association] who in 1948 published 
the medical student journal Chestpiece with Charles Xuereb as 
its first editor. The journal served to publish contributions from 
both medical students and qualified practitioners on various 
aspects of medical practice, generally of a review nature. The first 
volume 1948-56 saw the publication of 11 issues, often carrying 
articles written by university or hospital staff. A supplement to 
the first volume carried an address by the Minister of Health 
Dr. A. Schembri Adami who introduced the concept of the 
National Health Insurance scheme; while in 1949 the journal 
carried a reprint of Pope Pius XII’s pronouncement on artificial 
insemination and in 1950 carried an article on BCG inoculation 
by Dr. Andreas Widemann. The publication of the second 
volume was marked by a significant five year lapse in publication 
during 1959-63. The contribution in this volume similarly had 
a strong bias for medical staff contributions. The third volume 
starting in 1971, in a new format, had a lapse in publication 
during 1973-74 and 1977-78. The last issue of Chestpiece was 
published in 1979. The first issue of the third volume comments 
that the editors [J.V. Psaila and D. Vella Briffa] wished “further 
promoting contributions from students. This issue has had to 
rely, to some extent, on articles from our competent teachers, 
but we still feel that the bulk of the contents should come from 
the student.” This policy seems to have been maintained in the 
subsequent five issues, with the last issue carrying four articles 
authored by medical students and only one by a member of the 
medical faculty.11 The MMSA again embarked with a revived 
journal named Mediscope published during the period 1983-
1991 with a total of fourteen issues. The first editor was Mark 
Bugeja who continued in this role after his graduation.12 This 
journal was replaced in 1992 by the medical student journal 
Murmur which serves primarily as a medical student newsletter. 
The latter journal is still extant.13
The publication of a more scientific-based medical 
publication was undertaken in 1966 by the consultant staff at 
St. Luke’s Hospital, together with the Faculties of Medicine & 
Surgery and Dentistry. Entitled the St. Luke’s Hospital Gazette, 
this biannual journal set out to publish scientific articles 
reflecting the research activities and interests of the Maltese 
medical profession. It also received contributions from foreign 
specialists, including an article on heart transplantation by Prof. 
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Christian Barnard. There was also a strong bias in contributions 
related to the humanities as these pertain to medicine. Articles 
related to the medical humanities, including history, literature, 
ethics and law, accounted for 17.6% of the contributions. The 
first appointed editor was Dr. Emmanuel Agius. He was replaced 
by Dr. Roger Ellul-Micallef in 1975. The publication of this 
journal was interrupted as a result of the Trade Unionist conflict 
of 1977. The 11 published volumes had included a total of 296 
articles (Figure 1). The last volume published in 1976 is included 
in the Pubmed database.14
An attempt was made by the Faculty to re-establish 
publication of a medical journal in 1982 entitled Journal of the 
Malta Medical School, but these efforts were not successful.15 
A specialist annual journal was published in this interim 
period by the Association of Anaesthesiologists in Malta - Acta 
Anaesthesiological Melitensis with the aim of serving as a forum 
for the publication of research and review articles. The first 
Editorial Board was made up of Drs. N. Boskovski, N. Azzopardi, 
D. Spiteri, AKMA Zaman and J. Sedlecek. The first issue was 
published in November 1983. The journal unfortunately ceased 
publication after six issues in 1989. Besides the anaesthetists 
and other medical practitioners working in Malta, the journal 
attracted contributions from other countries such as Denmark, 
Belgium, Egypt, Czechoslovakia, and Poland.16 Another 
professional medical publication issued by a medical association 
representing a medical speciality is the journal It-Tabib tal-
Familja – Journal of the Malta College of Family Doctors first 
published by the Malta College of Family Doctors in 1991. This 
journal carries a broad selection of contributions generally of 
a review nature. The journal is still extant and is distributed to 
all Malta-registered medical practitioners.17
The Faculty of Medicine and Surgery did eventually re-
initiate the publication of a refereed medical journal in 1989 
under the title of Maltese Medical Journal, circulated to all 
the Malta-registered medical and dental practitioners The first 
series initiated publication under the editorship of Dr. Joseph 
L. Pace and was published biannually, except in the last two 
volumes that were published annually. The first series saw the 
publication of 12 annual volumes with 23 issues. The articles 
ranged from research articles, review articles, historical articles, 
and case presentations (Figure 2). It also carried local news items 
occurring in the medical community.18 
The journal lapsed publication in 2001, but the Faculty soon 
re-established a new editorial board under the chairmanship 
of Prof. J. Cacciottolo and Prof. J. Vassallo as editor. The new 
board revised the editorial policies and format of the journal 
now under the title Malta Medical Journal. The first issue of 
the new series was published in November 2002. The frequency 
of publication was gradually increased to quarterly issues, with 
supplements that carry the abstracts of the Malta Medical School 
Conference in 2003, 2006 and 2009. The journal continues 
to publish articles ranging from research articles, review 
articles, historical articles, and case presentations (Figure 2). 
All submitted contributions are peer-reviewed.19 This journal 
established itself on the Internet in 2003. This has helped the 
journal to significantly widen its circulation, so that during 2008 
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Figure 1: Subject matter in “St. Luke’s Hospital Gazette”
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the web-version was accessed by a total of 72781 visitors with 
230471 page hits annually. Of the visitors, 32298 visited the 
site only once while 5376 visited more than once. Visitors were 
the most active from the United States of America and Canada 
(59804 visitors), the European Union (8708 visitors including 
3866 from Malta), other European countries (654 visitors), 
Australasia (2096 visitors), African continent (263 visitors), 
with the remainder 1256 visitors were from various countries in 
the Middle East and South American continent. This increased 
circulation has helped the journal to achieve recognition and 
be included in a number of web-based professional databases 
including Scopus, Index Academicus, and the Directory of Open 
Access Journals. 
Another extant publication is The Synapse – The Medical 
Professionals’ Network first launched by Dr. Wilfred Galea in 
January 2001. This paper-based magazine supplements the 
web-based service offered by the Medical Professionals’ Network 
on the Internet launched in 1996. The paper-based publication 
carries short review medical and non-medical articles in an 
attempt to stimulate continuing professional development. 
It is distributed free of charge to all Malta-registered doctors, 
dentists and pharmacists.20
The Maltese professional have always strived to promote 
continuing professional education with efforts to keep updated 
through reference to foreign journals. The establishment 
of a regularly published journal further supported the CPE 
efforts while encouraging the local professionals to adopt a 
scientific outlook to their practice. These endeavours by the 
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Maltese Medical Journal
Malta Medical Journal
medical profession have been emulated by other paramedical 
professionals including the pharmacists and midwives who have 
also published dedicated professional journals. 
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receiving protease inhibitors is not recommended. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency of glucose-galactose malabsorption should not take this medicine. Pregnancy and lactation: See contra-indications. Drug interactions: 
Also refer to contraindications. CRESTOR is neither an inhibitor nor inducer of cytochrome P450 isoenzymes. CRESTOR may potentiate the anticoagulant effect of Vitamin K antagonists (e.g. warfarin). Decrease in CRESTOR levels seen when co-administered with erythromycin or antac-
ids containing aluminium and magnesium hydroxide. Increase in oral contraceptive level and hormone replacement therapy level is seen when co-administered with CRESTOR. Concomitant use of CRESTOR and gemifibrozil resulted in a 2-fold increase in rosuvastatin Cmax.  Concomitant 
use of CRESTOR and ezetimibe resulted in no change in AUC or Cmax for either drug; however a pharmacodynamic interaction in terms of adverse events cannot be ruled out. Protease inhibitors. Undesirable effects: Common: headache, dizziness, constipation, nausea, abdominal 
pain, myalgia, asthenia and diabetes in patients with fasting glucose 5.6 to 6.9mmol/L. Uncommon: pruritus, rash and urticaria. Rare: myopathy (including myositis), rhabdomyolysis, hypersensitivity reactions including angioedema, increased hepatic transaminases, pancreatitis. Very 
rare: jaundice, hepatitis, haematuria, polyneuropathy and memory loss and arthralgia. Other usually transient side effects: elevation in CK levels, proteinuria. Other adverse events listed as unknown: diarrhoea, Stevens-Johnson syndrome, oedema, cough and dyspnoea. The following 
adverse events have been reported with some statins: depression, sleep disturbances including insomnia and nightmares, sexual dysfunction and exceptional cases of interstitial lung disease, especially with long term therapy. Legal Category: POM. Marketing Authorisation Number 
(s): PA 970/57/1-4. Marketing Authorisation Holder: AstraZeneca UK Ltd, 600 Capability Green, Luton, LU1 3LU, UK. Further information is available on request from: AstraZeneca Pharmaceuticals (Ireland) Ltd., College Park House, 20 Nassau Street, Dublin 2 Telephone: (01) 
6097100; Updated 06/10 CRESTOR is a trademark of the AstraZeneca group of companies. Licensed from Shionogi & Co Ltd, Osaka, Japan. Date of preparation: July 2010. URN: 10/0396. 
References: 1. Crestor SmPC. 2. Jones PH, Davidson MH, Stein EA et al. Am J Cardiol 2003; 92 (2): 152-160. 3. Schuster H, Barter P, Stender S et al. Am Heart J 2004; 147 (4): 705-712. 4. Ballantyne C et al. Am Heart J 2006; 151 (5):975.e1-975.e9. 5. Faergeman O et al. Atheroscler 
Suppl 2006; 7(3):580, Abs Th-P16394. 6. Clearfield M et al. Atheroscler Suppl 2005; 6(1), Abs W16-p-014:104. 7. Leiter LA et al. Eur Heart Journal 2005; 26(1):581 Abs P3503; 8. Blasetto JW, Stein EA, Brown WV et al. Am J Cardiol 2003; 91(Suppl): 3C-10C.
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chief interventionist being Disraeli.
Possibilities were very good. With Constantinople in British 
and French hands, the Russian army could be supplied. The Czar 
government secure from its internal enemies - the  Bolshevists – 
could initiate a new Russian offensive in the East, thus relieving 
the Western Front from pressure.
Churchill thought that the Dardanelles could be forced by 
the navy alone. In conjunction with the French, the British sent 
the pre-dreadnaughts.  This led to a major disaster, the Turkish 
waters were infested with mines and the approaches with heavy 
fortified forts.  The allies lost a number of battleships through 
enemy activity and German submarines were reputed to be in 
the area.  Hence it was thought that the Gallipoli Peninsula 
should be cleared of the hostile troops by landing troops on it 
– the Anzacs, Austrialian and New Zeland troops who were in 
Egypt at that time.  However, the element of surprise had been 
lost and when the troops finally landed they found the Turkish 
troops ready for them.  No real progress was done and after a few 
months, in which thousands of Allied troops were either killed 
or wounded, they were evacuated from the Gallipoli beaches, 
Winston Churchill resigned and eventually the Czar regime 
collapsed. Luckily the United States came into war on the side 
of the allies and the Western front was saved.
Malta was warned to get itself prepared to receive the 
wounded of the Gallipoli campaign.  The Governor at that time 
was Lord Melhuen who was a very good organiser.  Plans were 
immediately started to turn Malta into a giant hospital.  At that 
time there were four hospitals in Malta, the Central Hospital for 
civilians, the Blue Sisters’ hospital for merchant seamen, Bighi 
hospital for the navy and Mtarfa Hospital for the army.  Their 
total capacity was about three hundred beds, if all the rooms 
and available space were utilized there would be five hundred 
beds – far short of what was necessary. The Holy Infirmary at 
Valletta was roped into service. Some new schools were turned 
into hospitals and barracks which had been vacated by the troops 
turned into hospitals. Originally Allied command in Egypt asked 
for 3000 beds.  However, with mounting injuries it was soon 
found that that extimate was not nearly enough and more bed 
space was created.  A hospital is totally useless without adequate 
staff, doctors, nurses, attendants, labourers, technicians, cooks, 
laundry people, etc., etc.
The soldiers invaded the Gallipoli Peninsula on the 25th April 
1915. Many soldiers were wounded or killed. Up to the end of 
May 1915, 38,000 soldiers were either killed or wounded. These 
figures will make us understand the extent of the problem facing 
the authorities over here. The first wounded reached Malta on 
the 4th May 1915. They were carried on hospital ships, painted 
white with a big red cross painted on their sides. When the 
people realized that the wounded of Gallipoli were entering the 
bastions, the  mood was very sombre. The harbour had the aspect 
of a sick ward in a general hospital, silence all around.
One thousand two hundred solders, wounded from the front 
were brought on that day. Barges went against the hospital ships 
and the injured soldiers were brought down very gently by the 
cranes on stretchers and from the barges onto the shore. From 
the quay they were taken to the Holy Infirmary at Valletta where 
they were examined by top British and Maltese doctors, from 
there they were sent to other centres according to their injuries. 
A Maltese doctor appointed by the Governor himself for such 
duties was Dr Robert Randon who was placed in charge of Fort 
Tigne, now turned into a hospital of about 1,000 beds.
The processes of wounded soldiers on stretchers drawn 
by mules and horses passed through Kingsway, now Republic 
street, in Valletta on its way to the Holy Infirmary.  It was 
described as that of Good Friday, silence reigned and people 
on each side on the pavements welcomed the soldiers with 
cigarettes, sweets, flowers and chocolate.  The wounded soldiers 
most of them very young showed their appreciation by waving 
to the people and from that day the close bond between Malta 
and Australia was born.  Indeed a lot of these soldiers died in 
Malta and they were buried at Braxia Cemetery at Pietà near 
where the football club now stands.
May I be permitted here to read Rupert Brooke poem The 
Soldier written in that period of time.
If I should die, think only this of me
That there in a corner of a foreign field
That is forever England.  There shall be
In that rich earth a richer dust concealed.
A dust whom England bore, shaped, made aware
Gave, once, her flowers to love, her ways to name,
A body of England’s , breathing English air,
Washed by the XX, blast by suns of home.
Perhaps if we were to substitute Australia for England here, 
we can better understand the atmosphere, the sorrow and 
anguish that reigned in Malta that summer of 1915.
Up till the end of May, 4000 wounded had arrived and 
they were bring treated in 8 hospitals.  By September, 10,000 
wounded had arrived.  By March 1916, there were 20,000 
hospital beds, in all 80,000 soldiers were treated in Malta.  A 
percentage of them found their grave in Malta.  Military funerals 
were the order of the day, sometimes with eight or more dead 
soldiers buried on the same day. Since these funerals were 
having a depressing effect on the general population, it was 
decided to conduct them from outside the limits of Floriana, 
from Portes des Bombes to Braxia cemetery.
The Gardens of Argotti, the Mall, and the streets of 
Valletta were all full of wounded soldiers.  Some of them had 
an amputated arm pushing at colleague in a wheelchair with 
amputated legs.  Some had bandaged heads, others were 
blind.  However, they were cheerful and made friends with 
the Maltese people who opened the doors of their homes and 
hearts to them.  Ladies organised tea parties and concerts for 
them.  They started to sponsor children by giving them cards 
found in cigarette boxes.  In general the soldiers who survived 
the Gallipoli experience were quite happy for things could have 
been far worse for them.  In all they were treated in 27 military 
hospitals, one of them being the newly built school of Sliema. 
Archbishop Caruana was asked to tell the parish priests not to 
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ring the bells to let the patients rest.  The Archbishop obliged 
and the bells stopped ringing.  
Ghajn Tuffieha was tunred into a giant camp for convalescent 
soldiers. In all there were 4,000 beds under tents.  Three 
hundred civilian and military doctors were employed.  Some 
top British surgeons came to Malta, like Balance and Garrod, 
and 1000 British nurses came from the UK.
Gradually things started to calm down.  It was obvious that 
the Allies were making no headway in Gallipoli and they were 
pushed back.  However, on the 25th December 1915 the British 
and the French landed in Salonika to help the Serbians.  The 
First World War started from Serbia. In the Balkan wars of 1911 
and 1912, Bulgaria was offered Macedonia but its share went 
to Greece and Serbia.  Hence Serbia was attacked by Bulgaria, 
and the British and French went to help.  This time the Maltese 
makeshift hospitals were filled with malaria and typhoid.  It is 
interesting to note that the first cardiac operation was done in 
Malta on a soldier who had been shot by a Bulgarian sniper.
As the Gallipoli and Salonika campaigns subsided so did the 
Maltese hospitals empty, to fill again by the Spanish Influenza 
victims.  Employment during the war and when the war finished 
there was massive unemployment in Malta.  A lot of ships had 
been sunk, food was scarce and hard to get, there was massive 
inflation and the safety valve of emigration non-existent since 
Australia had problems of its own.  With political aspirations 
on the increase, the unemployed workers looked at the political 
leaders like Sir Filippo Sciberras and the next scene was the 
Sette Gungio rites of 1919.
When the First World War was nearly over the so-called 
Spanish Flu appeared.  The pandemic killed more people than 
the war itself, although one can attribute it to the war itself. 
When there is mass movement of troops and civilians with the 
most basic requisites of hygiene ignored and non-existent, one 
can expect epidemics.  In WW1 Spain was neutral and the first 
reported cases came from Spain since the censorship of the media 
was free.  It appeared in the US where young people were being 
called for service in Europe by Widrow Witson, thousands died 
in their training camps.  It infected the allied army in Northern 
France where a depot was located and then spread to the German 
army.  In all there were three waves of this pandemic and it was 
characterized by fever, breathing problems, haemoptysis and 
cyanosis.  Hence our hospitals started to fill again on the 4th 
October 1918. The Government issued regulations to prevent 
the spread of the disease – avoiding overcrowding and general 
cleanliness.  Between the 1st September 1918 and 1st March 1919 
there were 651 deaths.  March was the high point of the third 
wave.  The Influenza continued onto 1920. In February and 
March 656 cases were reported with a mortality of over 30%. 
The total mortality of the 1918 – 1919 pandemic in Malta was 3 
per 1000 of the population.
On the 10th December 1917 His Excellency the Governer 
declared at the beginning of the session of the Council of 
Government. “I also desire to record my grateful recognition of 
the sympathetic hospitality which the people of Malta and Gozo 
have extend to the sick and wounded that have been brought 
during the war, of the support that they have given to the British 
Red Cross and the Order of St John of Jerusalem and the other 
charitable institutions that have been formed.”  This was not 
the first time that Malta took the role of a Nurse in Wartime 
and it is said that Malta had added a bright chapter to human 
history and the severance to its hospitals ever be named; for 
their sacrifice has once more been enthroned, and unselfishness, 
garbed in nurses’ cape or surgoens’ uniform, proclaimed the 
triumph of love.
